(function($) {
  var arr_logo = ['assets/images/andromeda.logo.jpg','assets/images/aries.logo.jpg','assets/images/asteroid.logo.jpg', 'assets/images/arurora.logo.jpg','assets/images/centaurus.logo.jpg','assets/images/charon.logo.jpg','assets/images/comets.logo.jpg','assets/images/corall.logo.jpg','assets/images/corona.logo.jpg','assets/images/cosmos.logo.jpg','assets/images/discovery.logo.jpg','assets/images/eclipse.logo.jpg','assets/images/explorer.logo.jpg','assets/images/gravity.logo.jpg','assets/images/iris.logo.jpg','assets/images/jupiter.logo.jpg','assets/images/jupiter.high-risk.logo.jpg','assets/images/lunar.logo.jpg','assets/images/mercury-I.logo.jpg','assets/images/mercury-II.logo.jpg','assets/images/meteor.logo.jpg','assets/images/orbital.logo.jpg','assets/images/orion.logo.jpg','assets/images/planet-I.logo.jpg','assets/images/planet-II.logo.jpg','assets/images/pluto.logo.jpg','assets/images/polaris.logo.jpg','assets/images/pulsar.logo.jpg','assets/images/radar.logo.jpg','assets/images/saturn.logo.jpg', 'assets/images/solar.logo.jpg','assets/images/starship.logo.jpg','assets/images/stellar.logo.jpg','assets/images/uranus.logo.jpg'],
      detail_arr_logo = ['assets/images/andromeda.study.logo.jpg','assets/images/aries.study.logo.jpg', 'assets/images/asteroid.study.logo.jpg','assets/images/arurora.study.logo.jpg','assets/images/logo-centaurus.jpg','assets/images/charon.study.logo.jpg','assets/images/comets.study.logo.jpg','assets/images/corall.study.logo.jpg','assets/images/corona.study.logo.jpg','assets/images/cosmos.study.logo.jpg','assets/images/discovery.study.logo.jpg','assets/images/eclipse.study.logo.jpg','assets/images/explorer.study.logo.jpg','assets/images/gravity.study.logo.jpg','assets/images/iris.study.logo.jpg','assets/images/jupiter.study.logo.jpg','assets/images/jupiter.high-risk.study.logo.jpg','assets/images/lunar.study.logo.jpg','assets/images/mercury-I.study.logo.jpg','assets/images/mercury-II.study.logo.jpg','assets/images/meteor.study.logo.jpg','assets/images/orbital.study.logo.jpg','assets/images/orion.study.logo.jpg','assets/images/planet-I.study.logo.jpg','assets/images/planet-II.study.logo.jpg','assets/images/pluto.study.logo.jpg','assets/images/polaris.study.logo.jpg','assets/images/pulsar.study.logo.jpg','assets/images/radar.study.logo.jpg ','assets/images/saturn.study.logo.jpg', 'assets/images/solar.study.logo.jpg','assets/images/starship.study.logo.jpg','assets/images/stellar.study.logo.jpg','assets/images/uranus.study.logo.jpg'],
      arr_no_of_patients = ['509 patients', '774 patients', '507 patients', '2776 patients', '1115 patients', '198 patients', '401 patients', '263 patients', '5011 patients', '214 patients', '6743 patients', '1036 patients', '469 patients', '833 patients', '740 patients', '17,802 patients', '<span style="width:512px;  text-align: left;">1558 patients - with 10-year Framingham Risk Score >20%, <span style="display: block;  text-align: left;"> 9302 patients - with SCORE risk  &ge;5%</span></span>', '825 patients', '3161 patients', '1993 patients', '984 patients', '8108 patients', '43 patients', '353 patients', '237 patients', '177 patients','871 patients', '996 patients', '461 patients', '1385 patients', '1632 patients', '696 patients', '2431 patients', '469 patients'],
      arr_objectives = ['To compare the effects of rosuvastatin and atorvastatin 10 and 20 mg on plasma lipid and lipoprotein profiles in patients with Type 2 diabetes mellitus','To compare the lipid-lowering efficacy and safety of rosuvastatin and atorvastatin in hypercholesterolaemic African-American adults', 'To assess whether very intensive statin therapy with rosuvastatin 40 mg could regress coronary atherosclerosis as determined by IVUS imaging','To investigate the effect of rosuvastatin therapy on cardiovascular events in patients undergoing regular haemodialysis treatment','To compare the effect of rosuvastatin 20 mg and atorvastatin 80 mg in decreasing the apoB/apoA-1 ratio and LDL-C concentration in patients with ACS and planned or anticipated percutaneous coronary intervention','To determine the safety, tolerability, and efficacy of low-to-intensive doses of rosuvastatin (5,10, and  20 mg) in children to adolescents over 2 years','To compare the efficacy and safety of rosuvastatin and atorvastatin in patients with metabolic syndrome','To compare the efficacy of rosuvastatin with atorvastatin in subjects with Type 2 diabetes','To determine whether adding rosuvastatin to standard therapy reduces the occurrence of cardiovascular events in older patients with heart failure','To investigate the effect of rosuvastatin on plaque regression by IVUS imaging in hypercholesterolaemic Japanese patients with stable CAD','To compare the efficacy of rosuvastatin 10 mg with atorvastatin 10 mg, simvastatin 20 mg, and pravastatin 40 mg in enabling patients to achieve 2003 European LDL-C goals (<100.0 or <115.0 mg/dL [<2.59 or <2.98 mmol/L], depending on risk category), after 12 weeks of therapy','To compare the efficacy and tolerability of force-titrated treatment with rosuvastatin (10&ndash;40 mg) or atorvastatin (10&ndash;80 mg) in high-risk patients with hypercholesterolaemia','To compare the efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe 10 mg for 6 weeks in high-risk patients with hypercholesterolaemia','To compare the efficacy and safety of rosuvastatin (10 or 20 mg) in combination with ezetimibe 10 mg, with that of a fixed-dose combination of simvastatin (40 or 80 mg) and ezetimibe 10 mg','To evaluate the lipid-modifying effects of rosuvastatin and atorvastatin in South Asian patients with hypercholesterolaemia','To investigate whether long-term treatment with rosuvastatin 20 mg decreases the rate of first major cardiovascular events in apparently healthy individuals without hyperlipidaemia but with elevated hsCRP','To investigate whether long-term treatment with rosuvastatin 20 mg decreases the rate of first major cardiovascular events in apparently healthy individuals, without hyperlipidaemia but with elevated hsCRP, at high cardiovascular risk','To compare the efficacy of once-daily regimens of rosuvastatin 20 mg and 40 mg with atorvastatin 80 mg in reducing LDL-C levels in patients with ACS','To evaluate the effects of switching from commonly used doses of atorvastatin, simvastatin, and pravastatin to lower doses of rosuvastatin on cholesterol goal achievement in high-risk patients','To examine the effects of switching from commonly used doses of atorvastatin and simvastatin to lower doses of rosuvastatin on cholesterol goal achievement in high-risk patients','To assess whether rosuvastatin 40 mg could slow progression and/or cause regression of carotid intima-media thickness (CIMT) over 2 years','To determine whether a compliance-enhancing program could increase the level of lipid control in patients treated with rosuvastatin','To assess the effects of rosuvastatin on carotid plaque volume and composition','To compare the effect of rosuvastatin and atorvastatin on urinary protien excretion in patients with Type 1 or 2 diabetes who had moderate proteinuria and mild hypercholesterolaemia prior to initiation of treatment','   To compare the effects of rosuvastatin and atorvastatin on urinary protein excretion in patients who had moderate proteinuria and mild  hypercholesterolaemia prior to initiation of treatment','To evaluate the efficacy and safety of rosuvastatin therapy for children and adolescents 10&ndash;17 years with familial hypercholesterolaemia (FH)','To investigate the efficacy and safety of rosuvastatin 40 mg and atorvastatin 80 mg in high-risk patients with hypercholesterolaemia','To compare the efficacy and safety of  rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolaemia', 'To compare the effects of rosuvastatin and atorvastatin on the LDL-C/HDL-C ratio in patients with cardiovascular disease and low HDL-C','To compare the effects of treatment with rosuvastatin 40 mg and atorvastatin 80 mg on atherosclerotic disease burden, as measured by IVUS, in patients with CAD','To evaluate the efficacy of rosuvastatin, atorvastatin, and simvastatin in achieving NCEP ATP III LDL-C goals in managed care patients at high risk for coronary heart disease','To compare the efficacy of rosuvastatin and atorvastatin in Hispanic-American patients with hypercholesterolaemia','To compare the LDL-C lowering efficacy of rosuvastatin to atorvastatin, simvastatin, and pravastatin across the dose range','To compare the effects of rosuvastatin with atorvastatin on LDL-C, other plasma lipids, and LDL-C goal achievement in patients with Type 2 diabetes'],
      arr_study_design = ['<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients &GreaterEqual;18 years with a diagnosis of Type 2 diabetes</li><li>Treatment with diet and/or glucose-lowering agents </li><li>Have at least 2 fasting blood glucose readings (or one reading with symptoms of hyperglycaemia) of at least 126.1 mg/dl (7.00 mmol/L) before randomisation</li><li>Plasma TG level of <530.9 mg/dl (<6.00 mmol/L)</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/andromeda.study-design-chart.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage change in LDL-C from basline to study end  (Week 16)</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percentage change in LDL-C, HDL-C, TC, non-HDL-C, TG, ApoB, ApoA-I, and ApoB/ApoA-I after 8 weeks </li><li>Percentage change in HDL-C, TC, non-HDL-C, TG, APoB, APoA-I, and APoB/ApoA-I after 16 weeks </li><li>Proportion of patients achieving 2003 Joint European Societies LDL-C (<96.5 mg/dL or  <2.50 mmol/L) and TC (<173.7 mg/dL or <4.50 mmol/L) goals</li></ul>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>African-American patients &ge;18 years</li><li>Diagnosed with type IIa or IIb hypercholesterolaemia</li><li>Fasting LDL &ge;160.0 mg/dL (&ge;4.14 mmol/L) and &le;300.0 mg/dL (&le;7.77 mmol/L)</li><li>Triglycerides <400.0 mg/dL (<4.52 mmol/L)</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/aries.study-design.jpg" style="width:639px; height:auto; margin: 0 0 0 17px;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage change in LDL-C from baseline to study end (Week 6)</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percentage change in HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, TG, ApoB, and ApoA-I after 6 weeks </li><li>Proportion of patients achieving NCEP ATP III LDL-C goal after 6 weeks</li></ul>', 
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Statin-na&iuml;ve patients &ge;18 years</li><li>Requiring clinically indicated coronary angiography</li><li>&ge;1 obstruction with >20% angiographic luminal diameter narrowing in any coronary vessel</li><li>TG <500.0 mg/dL (<5.65 mmol/L)</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/asteroid.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Change in percent atheroma volume (PAV) and change in total atheroma volume (TAV) in the 10-mm subsegment with the greatest disease severity at baseline</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Change in normalised TAV for the entire artery segment under investigation</li><li>Percentage change in LDL-C, HDL-C, TC, and LDL-C/HDL-C from baseline to study end</li></ul>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients 50&ndash;80 years</li><li>Patients with end-stage renal disease who have been receiving chronic haemodialysis or haemofiltration for &ge;3 months</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/aurora.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>The time to major CV event (non-fatal stroke, non-fatal MI, or CV death)</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Incidence of the individual components of the primary endpoint</li><li>All-cause mortality</li><li>Change in LDL-C, HDL-C, TC, and TG at 3 months</li></ul>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4> <ul class="criteria-list"><li>Patients &ge;18 years</li><li>Non-ST-elevation ACS, hospitalised within 48 hours of onset</li><li>PCI planned</li><li>Evidence of CAD</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/centaurus.study-design.jpg" style="width:639px; height:auto; margin: 10px 0 0 20px;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage change in ApoB/ApoA-1 ratio from baseline to study end (3 months)</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percentage change in ApoB/ApoA-1 ratio at 1 month</li><li>Percentage change in LDL-C at 1 and 3 months</li><li>Proportion of patients achieving the 2003 European or updated AHA/ACC LDL-C target of <100.0 mg/dL (<2.59 mmol/L) at 3 months</li><li>Proportion of patients reaching the updated NCEP ATP III LDL-C target of <70.0 mg/dL (<1.81 mmol/L) at 3 months</li></ul>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4>  <ul class="criteria-list"><li>Children and adolescents (6 to <18 years) with familial hypercholesterolaemia</li><li>Patients 6 to 10 years of age must be statin-na&iuml;ve</li> </ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/charon.study-design.jpg" style="width:639px; height:auto;"  alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li> Percentage change from baseline in LDL-C at 3, 12, and 24 months</li><li> Assessments of growth by assessment of height (including linear growth [cm and SD score]) and secondary characteristics of sexual maturation by Tanner staging</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percentage change from baseline in HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C,  non-HDL-C/HDL-C, TG, ApoB, ApoA-I, and ApoB/ApoA-I at 3, 12, and 24 months </li> <li>Assessments at baseline, 12, and 24 months of intima and media wall thickness of the carotid arteries  by sonography in at least 180 enrolled patients in comparison to at least 60 enrolled healthy siblings</li></ul>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients &ge;18 years</li><li>Metabolic syndrome</li><li>LDL-C &ge;130.0 mg/dL (&ge;3.36 mmol/L)</li><li>10-year CHD risk >10%</li><li>Statin-na&iuml;ve</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/comets.study-design.jpg" style="width:639px; height:auto;"  alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage change in LDL-C from baseline after 6 weeks of treatment</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percentage change in LDL-C, HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C,non-HDL-C/HDL-C, TG, ApoB, ApoA-I, and ApoB/ApoA-I after 12 weeks</li><li>Proportion of patients achieving LDL-C <100.0 mg/dL (<2.59 mmol/L) after 6 and 12 weeks</li></ul>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"> <li>Patients >18 years</li><li>Type 2 diabetes mellitus</li><li>HbA1c <10%</li><li>LDL-C values &ge;129.73 mg/dL (&ge;3.36 mmol/L) (statin-na&iuml;ve subjects) or >114.44 mg/dL to &le;193.05 mg/dL (>2.99 mmol/L to &le;5.00 mmol/L) (subjects who had taken a statin within 4 weeks of visit)</li><li>TG <400.0 mg/dL (<4.52 mmol/L) </li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/corall.study-design.jpg" style="width:639px; height:auto;"  alt="Study"/> </div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage change in the apoB/apoA-1 ratio from baseline to Week 6</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Change in the ApoB/ApoA-I ratio at Weeks 12 and 18</li><li>Percentage change in LDL-C at Weeks 6, 12, and 18</li><li>Proportion of patients achieving LDL-C <100.0 mg/dL (<2.59 mmol/L) at Weeks 6, 12, and 18</li></ul>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients &ge;60 years</li><li>Symptomatic, chronic systolic heart failure of ischaemic aetiology</li><li>Ejection fraction &le;40% (NYHA class III/IV) or &le;35% (NYHA class II)</li><li>Patients receiving optimal therapy at least 2 weeks before randomisation</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/corona.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Time to the first occurrence of cardiovascular death, non-fatal MI, or non-fatal stroke</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Individual components of the primary endpoint</li><li>Number of hospitalisations for cardiovascular causes</li></ul>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients 20&ndash;75 years</li><li>Patients with CAD undergoing elective coronary angiography or PCI</li><li>&ge;1 vessel segment with &ge;75% stenosis and &ge;1 vessel segment with &le;50% stenosis</li><li>LDL-C &ge;140.0 mg/dL (&ge;3.63 mmol/L) or TC &ge;220.0 mg/dL (&ge;5.70 mmol/L) (untreated patients)</li><li>LDL-C &ge;100.0 mg/dL (&ge;2.59 mmol/L) or TC &ge;180.0 mg/dL (&ge;4.66 mmol/L) (patients on lipid-lowering therapy)</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/cosmos.study-design.jpg" style="width:670px; height:auto;"  alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percent change in total atheroma volume (TAV) from baseline to Week 76</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percent change in lipids and lipoproteins from baseline</li></ul>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients &ge;18 years</li><li>Type IIa or IIb hypercholesterolaemia</li><li>10-year cardiovascular risk >20% or a history of CHD or other established atherosclerotic disease<sup>a</sup></li><li>Statin-na&iuml;ve or could be switched to another statin</li><li>LDL-C &ge;135.0 mg/dL (&ge;3.49 mmol/L) (na&iuml;ve patients), >120.0 mg/dL (>3.11 mmol/L) (switched patients)<sup>b</sup></li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/discovery.study-design.jpg" style="width:639px; height:auto;"  alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage of patients achieving 2003 European LDL-C goals at 12 weeks of treatment (rosuvastatin 10 vs. atorvastatin 10 mg)</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percentage of patients achieving 2003 European LDL-C goals after 12 weeks (all treatments) by component study and all rosuvastatin 10 mg vs. atorvastatin 10 mg</li></ul><p style="margin: 20px 0 0;"><sup>a</sup> Except for PENTA studies.</p><p><sup>b</sup> In the PENTA study, inclusion criteria included &ge;5.0 mg/dL (&ge;0.13 mmol/L) above NCEP ATP III target goal (ie, &ge;105.0 mg/dL, &ge;2.72 mmol/L [high risk], &ge;135.0 mg/dL, &ge;3.49 mmol/L [medium risk], &ge;165.0 mg/dL, &ge;4.27 mmol/L [low risk].</p>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients &ge;18 years</li><li>Statin na&iuml;ve</li><li>Hypercholesterolaemia</li><li>History of CHD, clinical evidence of atherosclerosis, or a 10-year CHD risk score >20%</li><li>LDL-C levels &ge;160.0 to <250.0 mg/dL (&ge;4.14 to <6.47 mmol/L) and within 15% of each other</li><li>Fasting TG <400.0 mg/dL (<4.52 mmol/L)</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/eclipse.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage of patients achieving the NCEP ATP III LDL-C goal of <100.0 mg/dL (<2.59 mmol/L) at 24 weeks</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percentage change in LDL-C, HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, TG, ApoB, ApoA-I, and ApoB/ApoA-I after Weeks 6, 12, 18, and 24</li><li>Percentage of very high-risk patients achieving the NCEP ATP III LDL-C goal <70.0 mg/dL (<1.81 mmol/L) at Weeks 6, 12, 18, and 24</li></ul>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients &ge;18 years</li><li>Hypercholesterolaemia</li><li>History of CHD or clinical evidence of atherosclerosis or a 10-year CHD risk score >20%</li><li>Mean of two most recent LDL-C levels was &ge;160.0 mg/dL and <250.0 mg/dL (&ge;4.14 mmol/L and <6.47 mmol/L) and within 15% of each other</li><li>Fasting TG <400.0 mg/dL (<4.52 mmol/L)</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/explorer.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage of patients achieving ATP III LDL-C goal (<100.0 mg/dL or <2.59 mmol/L) after 6 weeks</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percentage change in LDL-C, HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, TG, ApoB, ApoA-I, and ApoB/ApoA-I after 6 weeks</li><li>Percentage of patients achieving the updated NCEP ATP III goal <70.0 mg/dL (<1.81 mmol/L)</li></ul>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients &ge;18 years</li><li>Hypercholesterolaemia</li><li>History of CHD or CHD risk equivalent</li><li>Clinical evidence of atherosclerosis or 10-year Framingham risk score >20% for CHD</li><li>Fasting LDL-C 130.0&ndash;220.0 mg/dL (3.36&ndash;5.70 mmol/L)</li><li>Fasting TG <400.0 mg/dL (<4.52 mmol/L)</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/gravity.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage change in LDL-C at Week 12</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percentage change in HDL-C, TC, non-HDL-C, TG, lipid ratios, ApoB, and ApoA-I</li><li>Proportion of patients achieving LDL-C goals of <100.0 mg/dL (<2.59 mmol/L) or <70.0 mg/dL (<1.81 mmol/L)</li><li>Safety</li></ul>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>South Asian (ie, originating from India, Pakistan, Bangladesh, Sri Lanka, Nepal, or Bhutan)</li><li>Patients &ge;18 years</li><li>CHD <em>or</em> CHD risk equivalent and LDL-C &ge;100.0 mg/dL (&ge;2.59 mmol/L) <em>or</em> &ge;2 risk factors, 10-year CHD risk 10% to 20%, and LDL-C &ge;130.0 mg/dL (&ge;3.36 mmol/L) <em>or</em> 0 or 1 risk factor and LDL-C &ge;160.0 mg/dL (&ge;4.14 mmol/L)</li><li>TG <500.0 mg/dL (<5.65 mmol/L) during the lead-in phase</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/iris.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage change in LDL-C from baseline at 6 weeks</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percentage change in HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, TG, ApoB, and ApoB/ApoA-I at 6 weeks</li><li>Proportions of patients reaching NCEP ATP III LDL-C goal <70.0 mg/dL (<1.81 mmol/L) at 6 weeks</li></ul>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Men &ge;50 years; women &ge;60 years</li><li>No history of cardiovascular disease </li><li>Fasting LDL-C <130.0 mg/dL (<3.36 mmol/L)</li><li>CRP levels &ge;2.0 mg/L </li><li>TG <500.0 mg/dL (<5.65 mmol/L) on initial screening</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/jupiter.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Time to the first occurrence of a major cardiovascular event (defined as nonfatal myocardial infarction, nonfatal stroke, hospitalisation for unstable angina, an arterial revascularisation procedure, or confirmed death from cardiovascular causes)</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Individual components of the primary endpoint</li><li>Death from any cause</li></ul>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Men &ge;50 years; women &ge;60 years</li><li>No history of cardiovascular disease </li><li>Fasting LDL-C <130.0 mg/dL (<3.36 mmol/L)</li><li>CRP levels &ge;2.0 mg/L</li><li>TG <500.0 mg/dL (<5.65 mmol/L) on initial screening</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/jupiter-highrisk.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><ul><li>These data were <em>post-hoc</em> analyses performed at the request of the European health authorities</li><li>All of the JUPITER study participants were classified according to 10-year global risk estimates using the Framingham risk score and the European SCORE risk algorithm. The SCORE model is limited to ages 45&ndash;64 years, so to account for the large proportion of subjects enrolled  in JUPITER >65 years, a modification of the SCORE model was used in which the risk conferred by age was extrapolated for patients aged 65 or older (extrapolated model). <em>The extrapolated model is the model cited in the European CRESTOR  Summary  of the Product Characteristics</em>. An analysis was also performed using the SCORE algorithm capped at 65 years (capped model), in which all subjects  &ge;65 years were assigned the risk of a 64-year old</li></ul><ul><li>9% (n=1558) of the JUPITER population were considered to be high risk  in having a Framingham 10-year risk >20%</li><li>52% (n=9302) of the JUPITER  population were considered to be high risk  in having a 10-year SCORE risk &ge;5% using the extrapolated model </li><li>35% (n=6307) of the JUPITER  population were considered to be high risk  in having a 10-year SCORE risk &ge;5% using the capped model </li></ul><h4>EFFICACY ENDPOINTS:</h4><ul><li>Time to the first occurrence of nonfatal MI, nonfatal stroke, or death from cardiovascular causes, in each of the 3 high-risk populations </li><li>Individual components of this composite endpoint in each of the 3 high-risk patient populations</li></ul>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients 18&ndash;75 years</li><li>CAD and hospitalised for ACS within 48 hours of ischaemic symptoms</li><li>Na&iuml;ve of lipid-lowering therapies in the 4 weeks before randomisation</li><li>LDL-C >70.0 mg/dL (>1.81 mmol/L)</li><li>TG <500.0 mg/dL (<5.65 mmol/L)</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/lunar.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage change in LDL-C from baseline, averaged over measurements at 6 and 12 weeks</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percentage change from baseline in HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, TG, ApoB, ApoA-I, and ApoB/ApoA-I averaged over 6&ndash;12 weeks</li><li>Percentage change in high-sensitivity C-reactive protein averaged over 6&ndash;12 weeks</li></ul>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients &ge;18 years</li><li>History of CHD or other atherosclerotic disease, Type 2 diabetes, or a CHD risk >20% over 10 years</li><li>Fasting levels of LDL-C &ge;115.0 mg/dL (&ge;2.99 mmol/L) and triglycerides <400.0 mg/dL (<4.52 mmol/L)</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/mercury.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage of patients reaching the Joint European Societies LDL-C goal of <116.0 mg/dL (<3.00 mmol/L) at 16 weeks</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percentage of patients achieving the NCEP ATP III LDL-C goals at 16 weeks</li><li>Percentage change in LDL-C at 16 weeks</li></ul>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients &ge;18 years</li><li>Documented history of CHD or other atherosclerotic disease, diabetes, or ATP III-defined 10-year CHD risk >20%</li><li>Fasting LDL-C &ge;130.0 mg/dL to <250.0 mg/dL (&ge;3.36 mmol/L to <6.46 mmol/L)</li><li>Triglycerides <400.0 mg/dL (<4.52 mmol/L)</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/mercury2.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Proportion of patients achieving the NCEP ATP III LDL-C goal <100.0 mg/dL (<2.59 mmol/L) at Week 16</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percentage change in LDL-C at 16 weeks</li><li>Percentage of patients achieving the NCEP ATP III LDL-C goal <70.0 mg/dL (<1.81 mmol/L) at 16 weeks</li></ul>',
'<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Males 45&ndash;70 years; Females 55&ndash;70 years </li> <li>Asymptomatic for any atherosclerosis-related disease</li><li>Maximum CIMT of &ge;1.2 to <3.5 mm</li>  <li>LDL-C &ge;120.0 to <160.0 mg/dL (&ge;3.11 to <4.14 mmol/L) with &ge;2 risk  factors and a 10-year CHD risk of <10% </li>  <li>LDL-C 120 to <190 mg/dL (3.11 to <4.92 mmol/L) with no additional CHD risk factor  other than age</li> <li>HDL-C  &le;60.0 mg/dL (&le;1.55 mmol/L) </li> <li>TG <500.0 mg/dL (<5.65 mmol/L)</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/meteor.study-design.jpg" style="width:639px; height:auto;"  alt="Study"/> </div><h4>PRIMARY ENDPOINT:</h4> <ul> <li>Annualized rate of change in maximum CIMT based on all scans performed during the 2-year study period from each of the 12 carotid artery sites (near and far walls of the right and left common carotid artery, carotid bulb, and internal carotid artery)</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4> <ul><li>Annualized rate of change in maximum CIMT derived from the near and far walls of: <ul> <li>The right and left common carotid artery</li> <li>The right and left carotid bulb</li><li>The right and left internal carotid artery</li></ul></li><li>Annualized rate of change in mean CIMT for the near and far walls of the right and left common carotid artery </li><li>Percentage change in LDL-C, HDL-C, TC, non-HDL-C, and TG from baseline to study end</li> </ul>',
 '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients &ge;18 years with primary hypercholesterolaemia</li><li>Statin-na&iuml;ve patients: LDL-C &ge;115.0 mg/dL (&ge;2.98 mmol/L)</li><li>Patients on lipid-lowering medication, but for whom ongoing treatment was ineffective: LDL-C &ge;125.0 mg/dL (&ge;3.24 mmol/L)</li> <li>History of CHD, other atherosclerotic disease, 10-year CHD risk &ge;20%, or diabetes</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/orbital.study-design.jpg" style="width:639px; height:auto;"  alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage of patients achieving the 1998 European LDL-C treatment goals  (<115.0 mg/dL [<2.98 mmol/L]) after 3, 6, and 12 months of therapy</li> </ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percentage change from baseline in LDL-C and HDL-C</li></ul>',
  '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients  &ge;18 years</li><li>Neurologically asymptomatic</li><li>LDL-C &ge;100.0 to <250.0 mg/dL (&ge;2.59 to <6.47 mmol/L)</li> <li>16%&ndash;79% stenosis of &ge;1 carotid artery with a lipid/necrotic core as assessed by ultrasound and MRI</li> </ul> <div class="study-schema"><h4>STUDY SCHEMA:</h4> <img src="assets/images/orion.study-design.jpg" style="width:639px; height:auto;"  alt="Study"/></div><h4>ENDPOINTS:</h4><ul><li>Change in plaque morphology (lumen volume, wall volume, normalised wall index, mean wall thickness) over the study period</li><li>Change in plaque composition (percent lipid rich necrotic core [LRNC], percent calcification, and percent fibrous tissue) over the study period </li><li>Change in LDL-C and HDL-C over the study period</li></ul>',
   '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients &ge;18 years with Type 1 or 2 diabetes</li><li>Moderate proteinuria (urinary protein/creatinine ratio 500&ndash;5000 mg/g)</li><li>LDL-C &ge;90.0 mg/dL (&ge;2.33 mmol/L)</li><li>ACE inhibitor and/or ARB for &ge;3 months</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4> <img src="assets/images/planet-I.study-design.jpg" style="width:639px; height:auto;"  alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Change in urinary protein/creatinine ratio from baseline to Week 52</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Change in urinary protein/creatinine ratio from baseline to Week 26</li><li>Change in urinary albumin/creatinine ratio from baseline to Weeks 26 and 52</li><li>Change (%) in lipids and lipoproteins (LDL-C, HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, TG, ApoB, ApoA-I, and ApoB/ApoA-I) from baseline to Weeks 26 and 52</li> <li>Change in estimated GFR from baseline to Weeks 26 and 52 predicted from modified MDRD equation</li><li>Incidence and severity of adverse effects and abnormal laboratory data</li></ul> ',
 '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients &ge;18 years </li><li>Moderate proteinuria (urinary protein/creatinine ratio 500&ndash;5000 mg/g)</li><li>LDL-C &ge;90.0 mg/dL (&ge;2.33 mmol/L)</li><li>ACE inhibitor and/or ARB for &ge;3 months</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/planet-II.study-design.jpg" style="width:639px; height:auto;"  alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Change in urinary protein/creatinine ratio from baseline to Week 52</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Change in urinary protein/creatinine ratio from baseline to Week 26 </li><li>Change in urinary albumin/creatinine ratio from baseline to Weeks 26 and 52</li><li>Change (%) in lipids and lipoproteins (LDL-C, HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, TG, ApoB, ApoA-I, and ApoB/ApoA-I) from baseline to Weeks 26 and 52</li><li>Change in estimated GFR from baseline to Weeks 26 and 52 predicted from modified MDRD equation</li><li>Incidence and severity of adverse effects and abnormal laboratory data</li></ul>',
'<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients 10&ndash;17 years</li><li>Diagnosis of heterozygous FH by documentation of a genetic defect or pre-defined clinical criteria</li><li>Tanner stage &ge;II, with female subjects being at least 1 year post-menarche</li><li>Fasting LDL-C &ge;190.0 mg/dL (&ge;4.92 mmol/L)</li><li>LDL-C >160.0 mg/dL (>4.14 mmol/L) if family history of premature CVD or if the patient had &ge;2 other risk factors for CVD</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/pluto.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage change from baseline in LDL-C during the double-blind period</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percentage change in HDL-C, TC, TG, ApoB, and ApoA-I</li><li>Proportion of patients achieving LDL-C <110.0 mg/dL (<2.85 mmol/L) during the double-blind phase</li></ul>',
 '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients 45&ndash;80 years</li><li>Hypercholesterolaemia</li><li>History of CHD, clinical evidence of atherosclerosis, or a 10-year Framingham CHD risk score >20%</li><li>Mean fasting LDL-C levels at last 2 visits before randomisation &ge;160.0 to <250.0 mg/dL (&ge;4.14 to <6.47 mmol/L) and within 15% of each other</li><li>TG <400.0 mg/dL (<4.52 mmol/L)</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/polaris.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage change from baseline in LDL-C at 8 weeks</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Change in HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, TG, ApoB, ApoA-I, and ApoB/ApoA-I at Week 8</li><li>Proportion of patients achieving NCEP ATP III and European 2003 LDL-C treatment goals at Week 8</li></ul>',
 '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients &ge;18 years</li><li>Hypercholesterolaemia</li> <li>History of CHD, clinical evidence of atherosclerosis, or a CHD risk equivalent (diabetes mellitus or &ge;2 risk factors that confer a 10-year CHD risk score >20%)</li> <li> Two most recent fasting LDL-C levels were &ge;130.0 and <220.0 mg/dL (&ge;3.36 and <5.70 mmol/L) and within 15% of each other</li> <li> Fasting TG <400.0 mg/dL (<4.52 mmol/L)</li></ul> <div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/pulsar.study-design.jpg" style="width:639px; height:auto;"  alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul> <li>Percentage change in LDL-C from baseline to Week 6</li> </ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Change in HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, TG, ApoB, ApoA-I, and ApoB/ApoA-I at Week 6</li> <li>Proportion of patients achieving NCEP ATP III and European 2003 LDL-C treatment goals at Week 6</li> </ul>',
 '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients 40&ndash;80 years</li><li>Established cardiovascular disease, defined as one or more of the following:<ul><li>History of TIA or ischaemic stroke</li><li>Advanced carotid atherosclerosis</li><li>History of myocardial infarction or hospitalisation for UA</li><li>Angina pectoris with objective evidence of MI, coronary revascularisation or angiographic evidence of >50% stenosis in one or more major coronary artery</li></ul></li><li>Peripheral arterial disease</li><li>Fasting HDL-C concentrations of <40.0 mg/dL (<1.04 mmol/L) at Visit 1 and baseline</li><li>Triglycerides &le;400.0 mg/dL (&le;4.52 mmol/L) at Visit 1</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/radar.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage change in the LDL-C/HDL-C ratio from baseline to Week 6</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percentage change in LDL-C from baseline to Weeks 6, 12, and 18</li><li>Percentage of patients achieving the 2003 European LDL-C treatment goal <100.0 mg/dL (2.59 mmol/L) at Weeks 6, 12, and 18</li></ul>',
'<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients 18&ndash;75 years</li><li>Clinical indication for coronary angiography</li><li>Target coronary artery with stenosis >20% and &le;50%</li><li>LDL-C criteria<ul><li>No statin therapy in past 4 weeks: LDL-C >100.0 mg/dL (>2.59 mmol/L)</li><li>Statin therapy in past 4 weeks: LDL-C >80.0 mg/dL (>2.07 mmol/L)</li></ul></li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/saturn.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Change in percent atheroma volume (PAV) from baseline to 2 years</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Change in normalised total atheroma volume (TAV) from baseline to 2 years</li><li>Proportion of patients achieving an LDL-C <70.0 mg/dL (<1.81 mmol/L)</li></ul>',
 '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients &ge;18 years</li><li>Enrolled in a managed care health plan</li><li>Presence of CHD <em>or</em> CHD risk equivalents that consist of other clinical atherosclerotic disease, diabetes, or multiple CHD risk factors conferring a 10-year CHD risk >20%</li><li>LDL-C &ge;130.0 mg/dL to <250.0 mg/dL (&ge;3.36 mmol/L to <6.47 mmol/L)</li><li>TG <400.0 mg/dL (<4.52 mmol/L)</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/solar.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Proportion of patients achieving the NCEP ATP III high-risk LDL-C goal (<100.0 mg/dL; <2.59 mmol/L) at Week 6</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Proportion of patients achieving the NCEP ATP III high-risk LDL-C goal (<100.0 mg/dL; <2.59 mmol/L) at Week 12</li><li>Changes in LDL-C, HDL-C, TC, non-HDL-C, and TG at 12 weeks</li></ul>',
 '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Hispanic patients &ge;18 years</li><li>CHD, CHD risk equivalent, or a 10-year CHD risk &ge;10%</li><li>LDL-C &ge;130.0 to &le;300.0 mg/dL (&ge;3.36 to &le;7.77 mmol/L) on 2 measurements within 15% of each other</li><li>TG <400.0 mg/dL (<4.52 mmol/L)</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/starship.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage change in LDL-C from baseline to 6 weeks</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Change in HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, TG, ApoB, ApoA-I, and ApoB/apoA-I at Week 6</li><li>Proportion of patients achieving NCEP ATP III LDL treatment goals</li></ul>',
 '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients &ge;18 years with hypercholesterolaemia</li><li>LDL-C levels of &ge;160.0 and <250.0 mg/dL (&ge;4.14 and <6.47 mmol/L) at 2 most recent visits and within 15% of each other</li><li>TG <400.0 mg/dL (<4.52 mmol/L)</li></ul><div class="study-schema"><h4>STUDY SCHEMA*:</h4><img src="assets/images/stellar.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage change in LDL-C from baseline to 6 weeks</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percentage change in HDL-C from baseline to 6 weeks</li><li>Proportion of patients achieving 2003 LDL-C treatment goals</li></ul>',
 '<h4 class="criteria-heading">KEY INCLUSION CRITERIA:</h4><ul class="criteria-list"><li>Patients &ge;18 years</li><li>History of Type 2 diabetes for &ge;3 months</li><li>Treated with diet, oral anti-diabetic medication, insulin, or a combination of these treatments</li><li>Fasting LDL-C &ge;128.6 mg/dL (&ge;3.30 mmol/L)</li><li>TG <231.7 mg/dL (<6.00 mmol/L)</li></ul><div class="study-schema"><h4>STUDY SCHEMA:</h4><img src="assets/images/uranus.study-design.jpg" style="width:639px; height:auto;" alt="Study"/></div><h4>PRIMARY ENDPOINT:</h4><ul><li>Percentage change in LDL-C from baseline to 16 weeks</li></ul><h4>SELECTED SECONDARY ENDPOINTS:</h4><ul><li>Percentage change in LDL-C, HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, TG, ApoB, ApoA-I, and ApoB/ApoA-I at Week 4</li><li>Percentage of patients achieving the 1998 European LDL-C treatment goal <115.0 mg/dL (<3.00 mmol/L) at 16 weeks</li></ul>'],
      arr_baseline_characteristics = ['<h4>BASELINE CHARACTERISTICS<sup>a</sup>:</h4><img src="assets/images/andromeda.baseline-characteristics.jpg" alt="" style="width:660px; height:auto;"/>', '<h4>BASELINE CHARACTERISTICS:</h4><img src="assets/images/aries.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>', '<h4>BASELINE CHARACTERISTICS<sup>a</sup>:</h4><img src="assets/images/asteroid.baseline-characteristic.jpg" alt="characteristics" style="width:660px; height:auto;"/>','<div class="scroll-pane" ><h4>BASELINE CHARACTERISTICS<sup>a</sup>:</h4><img src="assets/images/aurora.baseline-character-1.jpg" alt="characteristics" style="width:660px; height:auto;"/><img src="assets/images/aurora.baseline-character-2.jpg" alt="characteristics" style="width:660px; height:auto; margin: 0 5px 0 0;"/></div>','<h4>BASELINE CHARACTERISTICS<sup>a</sup>:</h4> <img src="assets/images/centaurus.baseline-characteristics.jpg" alt="" style="width:660px; height:auto;"/>','<p class="content-not-available"> There is no content available at this time.</p>','<h4>BASELINE CHARACTERISTICS<sup>a</sup>:</h4><img src="assets/images/comets.baseline-characteristics.jpg" alt="" style="width:660px; height:auto;"/>','<h4>BASELINE CHARACTERISTICS:</h4><img src="assets/images/corall.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<h4>BASELINE CHARACTERISTICS<sup>a</sup>:</h4><img src="assets/images/corona.baseline-characreristics-1.jpg" alt="" style="width:660px; height:auto;"/><img src="assets/images/corona.baseline-characreristics-2.jpg" alt="" style="width:660px; height:auto; margin:0"/>','<h4>BASELINE CHARACTERISTICS:</h4><img src="assets/images/cosmos.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<h4>BASELINE CHARACTERISTICS:</h4><h5>Randomised Patient Characteristics at Baseline by Study From 5 Studies in the DISCOVERY Programme</h5><img src="assets/images/discovery.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<h4>BASELINE CHARACTERISTICS<sup>a</sup>:</h4><img src="assets/images/eclipse.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<h4>BASELINE CHARACTERISTICS<sup>a</sup>:</h4><img src="assets/images/explorer.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<p class="content-not-available"> There is no content available at this time.</p>','<h4>BASELINE CHARACTERISTICS<sup>a</sup>:</h4><img src="assets/images/iris.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<h4>BASELINE CHARACTERISTICS:</h4><img src="assets/images/jupiter.baseline-characreristics-1.jpg" alt="" style="width:660px; height:auto;"/><img src="assets/images/jupiter.baseline-characreristics-2.jpg" alt="" style="width:660px;height:auto;"/>','<h4>BASELINE CHARACTERISTICS:</h4><h5>Baseline Characteristics According to the Estimated 10-year Risk Defined by the Framingham Risk Score or the Systematic Coronary Risk Evaluation Risk Algorithm</h5><img src="assets/images/jupiter-highrisk.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<h4>BASELINE CHARACTERISTICS:</h4><img src="assets/images/lunar.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<h4>BASELINE CHARACTERISTICS:</h4><h5>Demographic and Baseline Characteristics by Period 1 Treatment</h5><img src="assets/images/mercury.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<h4>BASELINE CHARACTERISTICS:</h4><img src="assets/images/mercury2.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<h4>BASELINE CHARACTERISTICS:</h4><img src="assets/images/meteor.baseline-characreristics-1.jpg" alt="" style="width:660px; height:auto;"/><img src="assets/images/meteor.baseline-characreristics-2.jpg" alt="" style="width:660px; height:auto;"/>','<h4>BASELINE CHARACTERISTICS:</h4><img src="assets/images/orbital.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>',' <h4>BASELINE CHARACTERISTICS:</h4><img src="assets/images/orion.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<p class="content-not-available"> There is no content available at this time.</p>','<p class="content-not-available"> There is no content available at this time.</p>','<h4>BASELINE CHARACTERISTICS<sup>a</sup>:</h4><img src="assets/images/pluto.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<h4>BASELINE CHARACTERISTICS:</h4><img src="assets/images/polaris.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<h4>BASELINE CHARACTERISTICS:</h4><img src="assets/images/pulsar.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<h4>BASELINE CHARACTERISTICS:</h4><img src="assets/images/radar.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<h4>Baseline Characteristics of Patients in the ITT Population<sup>a</sup>:</h4><img src="assets/images/saturn.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<h4>BASELINE CHARACTERISTICS<sup>a</sup>:</h4><img src="assets/images/solar.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<h4>BASELINE CHARACTERISTICS:</h4><img src="assets/images/starship.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<h4>BASELINE CHARACTERISTICS:</h4><img src="assets/images/stellar.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>','<h4>BASELINE CHARACTERISTICS:</h4><img src="assets/images/uranus.baseline-characreristics.jpg" alt="" style="width:660px; height:auto;"/>'],
      arr_results = ['<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Mean Percentage Change in LDL-C at Week 16</h5><img src="assets/images/andromeda.chart-1.jpg" style="width:325px; height:auto; margin: 0 0 0 120px;" alt="chart"/></div><div class="result-secondary-endpoint"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Change in Lipid Profile at 16 Weeks</h5><img src="assets/images/andromeda.chart-2.jpg" style="width:552px; height:auto; margin: 0 0 0 120px;"  alt="chart"/><h5>Achievement of the European LDL-C Goal</h5><img src="assets/images/andromeda.chart-3.jpg" style="width:530px; height:auto; margin: 0 0 0 120px;"  alt="chart"/><div class="result-safty"><h5>RESULTS:</h5><h5>SAFETY</h5><ul><li>Both treatments were well tolerated, with similar overall incidences of AEs (48.4% with rosuvastatin vs. 53.7% with atorvastatin) and withdrawals because of AEs (5.9% vs. 5.1%, respectively)</li><li>There were 8 serious AEs, only one deemed to be related to study treatment (14.6 kg weight gain reported in one patient receiving rosuvastatin)</li><li>Overall, both treatments were associated with a similar, small reduction in weight during the study</li><li>Most frequent AEs overall were nasopharyngitis, lower respiratory tract infection, constipation, arthralgia, and diarrhoea</li><li>No cases of myopathy or rhabdomyolysis were reported in either treatment group</li><li>Six (6) patients (2.4%) receiving rosuvastatin and 2 patients (0.8%) receiving atorvastatin had treatment-emergent myalgia</li><li>Nine (9) and 8 patients receiving rosuvastatin and atorvastatin, respectively, showed clinically significant (>30%) increases in serum creatinine levels at 8 and/or 16 weeks<ul><li>Creatinine remained within normal range for the majority of these patients, with only 3 patients treated with rosuvastatin having  a 30% increase outside the normal range</li><li>Of patients with clinically significant increases in serum creatinine, levels returned to normal at 16 weeks in 10 patients, 2 patients  had abnormal values at both 8 and 16 weeks with no further follow-up, and 5 had abnormal values at Week 16 with no further follow-up</li></ul></li><li>There were no clinically relevant changes in hepatic enzymes (>3x ULN) or CK (>10x ULN) in either group, and no cases of renal or liver insufficiency were reported</li></ul></div></div>',
  '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Percentage Change in LDL-C From Baseline to Week 6</h5><img src="assets/images/aries.chart-1.jpg" style="width:510px; height:auto;  margin: 0 0 0 55px;" alt="chart"/></div><div class="result-secondary-endpoint"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Change in Lipid Profile at 6 Weeks</h5><img src="assets/images/aries.chart-2.jpg" style="width:675px; height:auto; margin: 0 0 0 17px;" alt="chart"/><h5>Achievement of the NCEP ATP III LDL-C Goal by Risk Category</h5><img src="assets/images/aries.chart-3.jpg"  style="width:675px; height:auto; margin: 0 0 0 17px;" alt="chart"/><div class="result-safty"><h5>RESULTS:</h5><h5>SAFETY</h5><ul><li>Both open-label statins were well tolerated during the study; the overall occurrence of adverse events was similar in the rosuvastatin and atorvastatin groups (34.4% vs. 33.6%, respectively)</li><li>No instances of myopathy or rhabdomyolysis occurred</li><li>The rate of myalgia was 2.6% and 3.6% for rosuvastatin 10 and 20 mg, and 2.6% and 1.0% for atorvastatin 10 and 20 mg, respectively</li><li>No patients had creatine kinase elevations >10x ULN</li><li>No increases in hepatic transaminases of >3x ULN were observed, and no symptom complexes suggestive of liver disturbance were observed in any patients</li><li>No clinically meaningful changes in renal biochemistry measures were seen and no patients had a doubling of their serum creatinine levels</li><li>Three (3) rosuvastatin-treated patients and 5 atorvastatin-treated patients had an increase in urine dipstick protein from none or trace at baseline to 2+; no patients had an increase that exceeded 2+ proteinuria</li></ul></div></div>', 
  '<div class="result-primary-endpoint"><h4>RESULTS: CO-PRIMARY ENDPOINT</h4><h5>Change in Median PAV</h5><img src="assets/images/asteroid.chart-1.jpg" style="width:440px; height:auto; margin: 0 0 0 130px;" alt="chart"/></div><div class="result-secondary-endpoint"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Change in Key IVUS Parameters</h5><img src="assets/images/asteroid.chart-2.jpg"" style="width:552px; height:auto; margin: 0 0 0 117px;" alt="chart"/><h5>Percentage Change<sup>a</sup> in LDL-C, HDL-C, TC, and LDL-C/HDL-C Ratio<h5><img src="assets/images/asteroid.chart-3.jpg" " style="width:552px; height:auto; margin: 0 0 0 110px;" alt="chart"/></div><div class="result-safety"><h4>RESULTS: SAFETY</h4><h5>Adverse Events, Drug Discontinuations, and Clinical Endpoints in the Safety Population (n=507)</h5><img src="assets/images/asteroid.result.jpg"  style="width:660px; height:auto;  margin: 0 0 0 22px;" alt="result-chart"/></div>',
  '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Kaplan-Meier Estimate of Time to First Major CV Event</h5><img src="assets/images/aurora.chart-1.jpg" style="width:490px; height:auto;  margin: 0 0 0 115px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA; margin: 15px 0 0;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Endpoints According to Study Group<sup>a</sup></h5><img src="assets/images/aurora.chart-2.jpg" style="width:670px; height:auto;  margin: 0 0 0 22px;" alt="chart"/><img src="assets/images/aurora.chart-3.jpg" style="width:670px; height:auto; margin: 0 0 0 22px;" alt="chart"/><h5>Changes in Lipids at 3 Months</h5><img src="assets/images/aurora.chart-4.jpg" style="width:658px; height:auto;  margin: 0 0 0 25px;" alt="chart"/></div><div class="result-safety" style="border-top: 2px solid #C7C2BA; margin: 15px 0 0;"><h4>RESULTS: SAFETY</h4><h5>Monitored AEs and Measured Laboratory Values in the Safety-Analysis Population<sup>a</sup></h5><img src="assets/images/aurora.chart-5.jpg" style="width:670px; height:auto;  margin: 0 0 0 22px;" alt="chart"/></div><img src="assets/images/aurora.chart-6.jpg" style="width:670px; height:auto;  margin: 0 0 0 22px;" alt="chart"/>',
  '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Percentage Change in ApoB/apoA-I Levels (ITT Population)</h5><img src="assets/images/centaurus.chart-1.jpg" style="width:540px; height:auto;   margin: 0 0 0 141px;"/></div> <div class="result-secondary-endpoint"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Percentage Change in LDL-C Levels (Protocol Population)</h5><img src="assets/images/centaurus.chart-2.jpg" style="width:540px; height:auto; margin: 0 0 0 141px;" alt="chart"/><h4> Proportion Achieving LDL-C Targets at 3 Months (ITT Population)</h4><img src="assets/images/centaurus.chart-3.jpg" style="width:540px; height:auto; margin: 0 0 0 141px;" alt="chart"/><div class="result-safety" style="border-top: 2px solid #C7C2BA; margin: 15px 0 0;"><h4>RESULTS: SAFETY</h4><img src="assets/images/centaurus.chart-4.jpg" style="width:665px; height:auto;  margin: 0 0 0 18px;" alt="chart"/></div></div>',
  '<p class="content-not-available"> There is no content available at this time.</p>',
  '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Percentage Change From Baseline in LDL-C Levels<sup>a</sup> at 6 Weeks</h5><img src="assets/images/comets.chart-1.jpg" style="width:540px; height:auto;   margin: 0 0 0 141px;" alt="chart"/></div><div class="result-secondary-endpoint"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Percent Change From Baseline in Lipid Profile at 6 Weeks</h5><img src="assets/images/comets.chart-2.jpg" style="width:660px; height:auto; margin: 0 0 0 25px;" alt="chart"/><h5>Percentage of Patients Achieving LDL-C <100.0 mg/dL (<2.59 mmol/L)</h5><img src="assets/images/comets.chart-3.jpg" style="width:540px; height:auto; margin: 0 0 0 141px;" alt="chart"/><div class="result-safty"><h5>RESULTS:</h5><h5>SAFETY</h5><h6>Treatment-emergent AEs, SAEs, Discontinuations Due to AEs, and Most Commonly Reported Treatment-emergent AEs<sup>a</sup> in Periods 1 and 2</h6><img src="assets/images/comets.chart-4.jpg" style="width:665px; height:auto;margin: 0 0 0 18px;" alt="chart"/></div></div>',
  '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Percentage Changes From Baseline ApoB/ApoA-I at Weeks 6, 12, and 18</h5><img src="assets/images/corall.chart-1.jpg" style="width:555px; height:auto; margin: 0 0 0 132px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Percentage Changes From Baseline in LDL-C at Weeks 6, 12, and 18</h5><img src="assets/images/corall.chart-2.jpg" style="width:555px; height:auto; margin: 0 0 0 132px;" alt="chart"/><h5>Patients Who Achieved ADA LDL-C Goal of <100.0 mg/dL (<2.59 mmol/L) (%)</h5><img src="assets/images/corall.chart-3.jpg" style="width:555px; height:auto; margin: 0 0 0 132px;" alt="chart"/><div class="result-safty"><h5>RESULTS:</h5><h5>SAFETY</h5><ul><li>Both treatments were well-tolerated and the overall occurrence of AEs associated with each treatment was similar (47% on rosuvastatin, 50% on atorvastatin)</li><li>The occurrence of SAEs was low (5% on rosuvastatin, 2% on atorvastatin)</li><li>Similarly, withdrawal from study treatment because of AEs was low (7% on rosuvastatin, 8% on atorvastatin)</li><li>No apparent differences were observed between treatment groups</li><li>No treatment-related SAEs were reported in either treatment group</li><li>The occurrence of myalgia, the most frequently reported AE, was similar in both groups, occurring in 5% of subjects receiving rosuvastatin and 11% of those receiving atorvastatin </li><li>No cases of myopathy were reported (CK >10x ULN and muscle symptoms)</li><li>One patient receiving atorvastatin developed clinically important abnormalities in ALT (>3x ULN)</li></ul></div></div>',
  '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>The Combined Endpoint of Cardiovascular Death or Nonfatal MI or Nonfatal Stroke (Time to First Event)</h5><img src="assets/images/corona.chart-1.jpg" style="width:490px; height:auto; margin: 0 0 0 115px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Number of Patients Suffering Any of the Components of the Primary Endpoint</h5><img src="assets/images/corona.chart-2.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/><h5>Total Number of Hospitalisations</h5><img src="assets/images/corona.chart-3.jpg" style="width:540px; height:auto; margin: 0 0 0 141px;" alt="chart"/><div class="result-safty" style="border-top: 2px solid #C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><h6>Side Effects and Adverse Events<sup>a</sup></h6><img src="assets/images/corona.chart-4.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/><img src="assets/images/corona.chart-5.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/></div></div>',
  '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Percentage Change in Total Atheroma Volume (TAV)</h5><img src="assets/images/cosmos.chart-1.jpg" style="width:490px; height:auto; margin: 0 0 0 137px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Change in Lipids and Lipoproteins From Baseline (n=126)</h5><img src="assets/images/cosmos.chart-2.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/><div class="result-safty" style="border-top: 2px solid #C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><h6>Adverse Events in 213 Patients During the Observation Period (76 Weeks)</h6><img src="assets/images/cosmos.chart-3.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/></div></div>',
  '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Percentage of Patients Achieving 2003 European LDL-C<sup>a</sup> With RSV Compared With ATV (ITT Population)</h5><img src="assets/images/discovery.chart-1.jpg" style="width:550px; height:auto; margin: 0 0 0 142px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Meta-analysis of Proportion of Patients Achieving Goal for Each Statin in the 5 Studies in the DISCOVERY Programme<sup>a</sup></h5><img src="assets/images/discovery.chart-2.jpg" style="width:615px; height:auto; margin: 0 0 0 76px;" alt="chart"/><div class="result-safty" style="border-top: 2px solid #C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><h6>Summary of AEs by Study From 5 Studies in the DISCOVERY Programme<sup>a</sup></h6><img src="assets/images/discovery.chart-3.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/><h6>Clinically Relevant Changes in Laboratory Values by Study From 5 Studies in the DISCOVERY Programme</h6><img src="assets/images/discovery.chart-4.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/></div></div>',
  '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Patients Achieving NCEP ATP III LDL-C Goal of <100.0 mg/dL (<2.59 mmol/L) at Week 24</h5><img src="assets/images/eclipse.chart-1.jpg" style="width:475px; height:auto; margin: 0 0 0 134px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Adjusted Mean Percentage Changes From Baseline in Lipid and Apo Levels After 6, 12, 18, and 24 Weeks of Treatment (ITT Population)</h5><img src="assets/images/eclipse.chart-2.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/><h5>Achievement of Updated NCEP ATP III LDL-C Goal (<70.0 mg/dL; <1.81 mmol/L) by Very High-Risk Patients</h5><img src="assets/images/eclipse.chart-3.jpg" style="width:550px; height:auto; margin: 0 0 0 142px;" alt="chart"/><div class="result-safty" style="border-top: 2px solid #C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><h6>Number of Patients With AEs or Changes in Laboratory Values (Randomised Safety Population)</h6><img src="assets/images/eclipse.chart-4.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/></div></div>',
  '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Percentage of Patients Achieving LDL-C Target of <100.0 mg/dL (<2.59 mmol/L) at Week 6</h5><img src="assets/images/explorer.chart-1.jpg" style="width:475px; height:auto; margin: 0 0 0 134px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Mean Percentage Change From Baseline in Lipid, Lipoprotein, and Inflammatory Marker Levels at Week 6 (ITT Population)</h5><img src="assets/images/explorer.chart-2.jpg" style="width:615px; height:auto; margin: 0 0 0 76px;" alt="chart"/><h5>Percentage of Very High-Risk Patients Achieving LDL-C Target of <70.0 mg/dL (<1.81 mmol/L) at Week 6</h5><img src="assets/images/explorer.chart-3.jpg" style="width:475px; height:auto; margin: 0 0 0 134px;" alt="chart"/><div class="result-safty" style="border-top: 2px solid #C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><h6>Most Frequently Reported AEs<sup>a</sup></h6><img src="assets/images/explorer.chart-4.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/></div></div>',
  '<p class="content-not-available"> There is no content available at this time.</p>',
  '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Percentage Change From Baseline for LDL-C at Week 6</h5><img src="assets/images/iris.chart-1.jpg" style="width:545px; height:auto; margin: 0 0 0 140px;" alt="chart"/></div><div class="result-secondary-endpoint"style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>LSM Percentage Change From Baseline in Lipid Levels at Week 6</h5><img src="assets/images/iris.chart-2.jpg" style="width:650px; height:auto; margin: 0 0 0 30px;" alt="chart"/><h5>Percentage of High-Risk Patients Achieving LDL-C Goal of <70.0 mg/dL (<1.81 mmol/L) at Week 6</h5><img src="assets/images/iris.chart-3.jpg" style="width:475px; height:auto; margin: 0 0 0 126px;" alt="chart"/><div class="result-safty" style="border-top: 2px solid #C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><img src="assets/images/iris.chart-4.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/></div></div>',
  '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Time to First Occurrence of a CV Death, Nonfatal Stroke, Nonfatal MI, Unstable Angina, or Arterial Revascularisation</h5><img src="assets/images/jupiter.chart-1.jpg" style="width:590px; height:auto; margin: 0 0 0 70px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Incidence of Death From Any Cause</h5><img src="assets/images/jupiter.chart-2.jpg" style="width:590px; height:auto; margin: 0 0 0 70px;" alt="chart"/><h5 style="margin: 30px 20px 0">Outcomes According to Study Group</h5><img src="assets/images/jupiter.chart-3.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/><div class="result-safty" style="border-top: 2px solid #C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><h6>Monitored AEs, Measured Laboratory Values, and Other Reported Events of Interest During the Follow-up Period<sup>a</sup></h6><img src="assets/images/jupiter.chart-4.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/></div></div>',
  '<div class="result-primary-endpoint"><h4>RESULTS: EFFICACY ENDPOINT</h4><h5 style="padding:0px;">Post-Hoc Analyses of JUPITER in High-Risk Patients (10-Year Framingham >20%)</h5><h5 style="margin:0px 20px;">Incidence of Cardiovascular Death, MI, or Stroke</h5><img src="assets/images/jupiter-highrisk.chart-1.jpg" style="width:525px; height:auto; margin: 0 0 0 135px;" alt:"chart"/><h5 style="padding:0px;">Post-Hoc Analyses of JUPITER in High-Risk Patients (SCORE &ge;5%; Extrapolated Model)</h5><h5 style="margin:0px 20px;">Incidence of Cardiovascular Death, MI, or Stroke</h5><img src="assets/images/jupiter-highrisk.chart-2.jpg" style="width:525px; height:auto; margin: 0 0 0 135px;" alt:"chart"/><h5>Major Cardiovascular Events and All-Cause Mortality in High-Risk Subgroups</h5><img src="assets/images/jupiter-highrisk.chart-3.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt:"chart"/> </div><div class="result-safty" style="border-top: 2px solid  C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><h6>Adverse Events and Laboratory Abnormalities in High-Risk Subgroups</h6><img src="assets/images/jupiter-highrisk.chart-4.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/></div>',
  '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Mean Percentage Change From Baseline in LDL-C (Average of Week 6 and Week 12 Measurements)</h5><img src="assets/images/lunar.chart-1.jpg" style="width:540px; height:auto;   margin: 0 0 0 120px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Mean Percentage Change From Baseline in HDL-C (Average of Week 6 and Week 12 Measurements)</h5><img src="assets/images/lunar.chart-2.jpg" style="width:540px; height:auto; margin: 0 0 0 120px;;" alt="chart"/><h5>Mean Percentage Change From Baseline in Lipid and Related Parameters (Average of Week 6 and Week 12 Measurements)</h5><img src="assets/images/lunar.chart-3.jpg" style="width:620px; height:auto; margin: 0 0 0 60px;" alt="chart"/><div class="result-safty" style="border-top: 2px solid #C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><h6>AEs Occurring in >5% of Patients in any Treatment Group</h6><img src="assets/images/lunar.chart-4.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/></div></div>',
  '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Patients Reaching Joint European Societies LDL-C Goal<sup>a</sup> <116.0 mg/dL (<3.00 mmol/L) at Week 16</h5><img src="assets/images/mercury.chart-1.jpg" style="width:550px; height:auto; margin: 0 0 0 100px;" alt="chart"/></div> <div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Patients Reaching ATP III LDL-C Goal<sup>a</sup> at Week 16</h5><img src="assets/images/mercury.chart-2.jpg" style="width:550px; height:auto; margin: 0 0 0 100px;" alt="chart"/><h5>Change in LDL-C at Week 16</h5><img src="assets/images/mercury.chart-3.jpg" style="width:550px; height:auto; margin: 0 0 0 100px;" alt="chart"/><div class="result-safty" style="border-top: 2px solid #C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><ul><li>Throughout this 16-week, 2-period trial, all study treatments were well tolerated</li><li>The overall occurrence of adverse events associated with each treatment was generally similar, and the occurrence of deaths, serious adverse events, and withdrawals from the trial due to adverse events was low, with no differences noted among the treatment groups</li><li>The occurrence of myalgia was low and similar between treatments, occurring in 1.9% of patients in Period 1 and 0.9% of patients in Period 2</li><li>No cases of myopathy (CK >10x ULN and muscle symptoms) were reported</li><li>Asymptomatic increases in CK >10x ULN were observed in 1 patient receiving atorvastatin 20 mg and 1 receiving rosuvastatin 10 mg (Arm 2); these elevations resolved during continued study treatment</li><li>No patients had clinically significant elevations in hepatic transaminases (3x ULN on 2 consecutive occasions)</li></ul></div></div>',
  '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Patients Achieving LDL-C Target of <100.0 mg/dL (<2.59 mmol/L) at Week 16</h5><img src="assets/images/mercury2.chart-1.jpg" style="width:550px; height:auto; margin: 0 0 0 88px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Change in LDL-C at 16 Weeks</h5><img src="assets/images/mercury2.chart-2.jpg" style="width:550px; height:auto; margin: 0 0 0 88px;" alt="chart"/><h5>Patients Achieving LDL-C Target of <70.0 mg/dL (<1.81 mmol/L) at Week 16</h5><img src="assets/images/mercury2.chart-3.jpg" style="width:550px; height:auto; margin: 0 0 0 88px;" alt="chart"/><div class="result-safty" style="border-top: 2px solid #C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><h6>Muscle, Hepatic, and Renal AEs in Period 1</h6><img src="assets/images/mercury2.chart-4.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/><h6>Muscle, Hepatic, and Renal AEs in Period 2</h6><img src="assets/images/mercury2.chart-5.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/></div></div>',
  '<div class="result-primary-endpoint"> <h4>RESULTS: PRIMARY ENDPOINT</h4><h5 style="padding:0;">Rate of Change of Maximum IMT at 12 Carotid Sites</h5><h5 style="margin:0 0 0 20px;">RSV vs. PBO</h5><img src="assets/images/meteor.chart-1.jpg" style="width:560px; height:auto; margin: 0 0 0 113px;" alt="chart"/> </div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"> <h4>RESULTS: SECONDARY ENDPOINTS</h4> <h5 style="padding:0;">Changes in Secondary Endpoints</h5><h5 style="margin:0 0 0 20px;">Change in CIMT, mm/y (95% CI)</h5> <img src="assets/images/meteor.chart-2.jpg" style="width:505px; height:auto; margin: 0 0 0 180px;" alt="chart"/>  <h5 style="margin:40px 20px 0;">Changes<sup>a</sup> in LDL-C, HDL-C, TC, Non-HDL-C, and TG</h5> <img src="assets/images/meteor.chart-3.jpg" style="width:555px; height:auto; margin: 0 0 0 140px;" alt="chart"/>  <div class="result-safty"> <h5>RESULTS:</h5><h5>SAFETY</h5><img src="assets/images/meteor.chart-4.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/> </div></div>',
  '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Patients Achieving LDL-C <115.0 mg/dL (<2.98 mmol/L)</h5><img src="assets/images/orbital.chart-1.jpg" style="width:555px; height:auto; margin: 0 0 0 125px; padding: 0 0 25px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Percentage Change<sup>a</sup> in LDL-C and HDL-C During 12-Month Treatment Period</h5><img src="assets/images/orbital.chart-2.jpg" style="width:555px; height:auto; padding: 0 0 25px; margin: 0 0 0 125px;" alt="chart"/> <div class="result-safty"><h5>RESULTS:</h5><h5>SAFETY</h5><h6>Adverse Events</h6><img src="assets/images/orbital.chart-3.jpg" style="width:660px; height:auto; margin: 0 0 0 34px;" alt="chart"/> </div></div>',
  ' <div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Change in Plaque Morphology</h5><img src="assets/images/orion.chart-1.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/><h5>Changes in Plaque Composition</h5><img src="assets/images/orion.chart-2.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/><h5>Change in LDL-C and HDL-C</h5><img src="assets/images/orion.chart-3.jpg" style="width:555px; height:auto; margin: 0 0 0 140px;" alt="chart"/></div> <div class="result-safty"><h5>RESULTS:</h5><h5>SAFETY</h5><ul><li>Four (4) of 43 subjects did not complete the study due to: AE (n=2), withdrawn consent (n=1), and other reasons (n=1)</li><li>Of the 39 patients who completed the study, all remained asymptomatic</li></ul></div>',
  '<p class="content-not-available"> There is no content available at this time.</p>',
  '<p class="content-not-available"> There is no content available at this time.</p>',
 '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Percentage Change in LDL-C From Baseline to Week 12</h5><img src="assets/images/pluto.chart-1.jpg" style="width: 555px; height: auto; margin: 0 0 0 125px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Percentage Change From Baseline to Week 12<sup>a</sup></h5><img src="assets/images/pluto.chart-2.jpg" style="width:555px; height:auto; margin: 0 0 0 125px;" alt="chart"/><h5>Percentage of Patients Achieving LDL-C <110.0 mg/dL (<2.85 mmol/L) During the Double-Blind Phase</h5><img src="assets/images/pluto.chart-3.jpg" style="width:555px; height: auto; margin: 0 0 0 125px;" alt="chart"/><div class="result-safty" style="border-top: 2px solid #C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><h6>Change From Baseline at End of Double-Blind Phase (Safety Population, n=176)</h6><img src="assets/images/pluto.chart-4.jpg" style="width: 660px; height:auto; margin: 0 0 0 22px;" alt="chart"/></div></div>',
  '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Change From Baseline in LDL-C Levels at Week 8 (ITT Population)</h5><img src="assets/images/polaris.chart-1.jpg" style="width:550px; height:auto; margin: 0 0 0 107px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Change From Baseline in Lipoprotein and Lipid Levels at Week 8 (ITT Population)<sup>a</sup></h5><img src="assets/images/polaris.chart-2.jpg" style="width:655px; height:auto; margin: 0 0 0 45px;" alt="chart"/><h5 style="margin:20px 20px 0; padding: 0 0 15px;">LDL-C Goal Achievement at Week 8</h5><img src="assets/images/polaris.chart-3.jpg" style="width:555px; height:auto; margin: 0 0 0 132px;" alt="chart"/><div class="result-safty" style="border-top: 2px solid #C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><ul><li>Both treatments were well tolerated and the overall frequencies and types of AEs were similar in the 2 treatment groups</li><li>The proportion of patients in the safety population who discontinued treatment as a result of any AE, or drug-related AE was low (rosuvastatin group 5.1% and 2.5%, respectively; atorvastatin group 6.2% and 4.8%, respectively)</li><li>Myalgia was the most commonly reported drug-related AE and was reported by 3.0% and 3.6% of patients in the rosuvastatin and atorvastatin groups, respectively</li><li>No cases of myopathy were reported during the study</li><li>One (1) patient had an elevation in CK (>10x ULN) while receiving atorvastatin 40 mg, but this was not associated with any symptoms and the patient remained in the study</li><li>There were no reported cases of rhabdomyolysis, defined as muscle symptoms plus CK >10x ULN plus an elevation in creatinine or urinary abnormalities</li><li>Four (4) patients (all receiving atorvastatin 80 mg) experienced a clinically important elevation in ALT (>3x ULN on 2 consecutive occasions); none of these patients experienced associated symptoms</li><li>Low frequencies of proteinuria (change in dipstick protein from none or trace at baseline to at least ++ during the study period) were observed during protocol mandated urinalysis testing in both the rosuvastatin (4.1%) and atorvastatin (1.0%) groups. At Week 26 the frequencies were 2.3% and 0.3%, respectively</li><li>Proteinuria was generally transient in nature with most cases returning towards baseline values by the last study visit. One (1) patient on rosuvastatin 40 mg in whom proteinuria persisted at the end of the study was negative for urinary protein on a follow-up visit (2.5 months post-study)</li><li>A post hoc analysis was performed on the changes in estimated glomerular filtration rate (eGFR) in the 2 treatment groups. Both rosuvastatin and atorvastatin treatment resulted in an increase in eGFR from baseline to Week 26; mean levels increased from 70.7 to 71.9 mL/min/1.73 m<sup>2</sup> in rosuvastatin-treated patients, and from 70.3 to 72.2 mL/min/1.73 m<sup>2</sup> in atorvastatin-treated patients</li><li>At Week 26, both of these increases were significantly different from baseline (mean percentage increase 2.5% [95% CI: 0.9&ndash;4.1] for rosuvastatin and 3.2% [95% CI: 2.0&ndash;4.5] for atorvastatin)</li></ul></div></div>',
 '<div class="result-primary-endpoint"> <h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Change From Baseline in LDL-C After 6 Weeks of Treatment (ITT Population)</h5><img src="assets/images/pulsar.chart-1.jpg" style="width:540px; height:auto; margin: 0 0 0 96px;" alt="chart"/></div> <div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Change From Baseline in Lipoprotein and Lipid Levels After 6 Weeks of Treatment (ITT Population)</h5><img src="assets/images/pulsar.chart-2.jpg" style="width:650px; height:auto; margin: 0 0 0 40px;" alt="chart"/> <h5>LDL-C Goal Achievement at Week 6</h5><img src="assets/images/pulsar.chart-3.jpg" style="width:555px; height:auto; margin: 0 0 0 132px;" alt="chart"/> <div class="result-safty"><h5>RESULTS:</h5> <h5>SAFETY</h5> <ul><li> Both treatments were well tolerated and the overall frequency and type of AEs were similar between treatment groups</li><li>An AE was experienced by 27.5% patients receiving rosuvastatin 10 mg and 26.1% of those receiving atorvastatin 20 mg; most were of mild-to-moderate intensity (94.2% and 96.1%, respectively) and a small number were classified as severe (5.8% and 3.9%, respectively)</li><li>A small number of patients discontinued treatment as a result of an AE or a drug-related AE (2.8% and 2.4% for rosuvastatin 10 mg, 2.2% and 2.0% for atorvastatin 20 mg, respectively)</li><li>Thirty-seven (37) patients reported myalgia: 24 (4.8%) in the rosuvastatin 10 mg group and 13 (2.6%) in the atorvastatin 20 mg group; 13 (2.6%) and 7 (1.4%) were thought to be treatment-related, and 4 (0.8%) and 1 (0.2%) cases resulted in withdrawal from the study</li><li>None of the 37 patients with reported myalgia had clinically important elevations in CK levels (>10x ULN) or even CK >3x ULN </li><li>One additional patient receiving rosuvastatin 10 mg had an increase in CK of >5x ULN, but this was not associated with muscle symptoms and not considered clinically important</li> <li>Clinically important elevations in ALT (>3x ULN on 2 consecutive occasions) were recorded for 1 patient receiving atorvastatin 20 mg, although this was not considered to be drug-related</li><li>No patients showed an increase in serum creatinine >50% from baseline and > ULN with either treatment</li><li>There were no clinically important abnormalities in urinalysis and no treatment-related trends were reported, with a low incidence of proteinuria (increase in dipstick positive urine protein from "none" or "trace" at baseline to "&ge;++" at Week 6) (0.6% in both groups)</li><li>No cases of rhabdomyolysis, myopathy, or acute renal failure were observed</li> </ul></div></div>',
 '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Mean Change From Baseline in LDL-C/HDL-C Ratio at Week 6</h5><img src="assets/images/radar.chart-1.jpg" style="width:400px; height:auto; margin: 0 0 0 113px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Mean Percentage Change From Baseline in LDL-C at Weeks 6, 12, and 18</h5><img src="assets/images/radar.chart-2.jpg" style="width:555px; height:auto; margin: 0 0 0 130px;" alt="chart"/><h5>Percentage of Patients Achieving 2003 European LDL-C Goal (<100.0 mg/dL [<2.59 mmol/L])</h5><img src="assets/images/radar.chart-3.jpg" style="width:555px; height:auto; margin: 0 0 0 130px;" alt="chart"/><div class="result-safty" style="border-top: 2px solid #C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><ul><li>Both treatments were well tolerated up to maximal recommended doses</li><li>The overall occurrence of adverse events associated with each treatment was similar, and the occurrence of deaths, serious adverse events, and withdrawals due to adverse events was low, with no differences noted between treatment groups</li><li>The incidence of myalgia was similar in the rosuvastatin and atorvastatin treatment groups (7% vs. 8%, respectively)</li><li>No cases of myopathy (creatine kinase >10x ULN and muscle symptoms) were reported</li><li>One patient receiving atorvastatin had a clinically important increase in creatine kinase (>10x ULN); however; this was not accompanied by muscle symptoms</li><li>During the course of the study, serum creatinine levels decreased in both treatment groups, with no difference between treatments<ul><li>8.5% change from baseline in the rosuvastatin group (<em>P</em> <0.0001) and 8.7% change from baseline in the atorvastatin group (<em>P</em> <0.0001)</li></ul></li><li>Glomerular filtration rate was determined at baseline and the end of the treatment period using the Modified Diet in Renal Disease (MDRD) equation; a slight increase was noted in both treatment groups, with no difference between treatments<ul><li>9.6% change from baseline in the rosuvastatin group (<em>P</em> <0.0001) and 9.9% change from baseline in the atorvastatin group (<em>P</em> <0.0001)</li></ul></li><li>There were no clinically important abnormalities in alanine aminotransferase or aspartate aminotransferase activity (>3x ULN) during the study</li></ul></div></div>','<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Change in PAV From Baseline</h5><img src="assets/images/saturn.chart-1.jpg" style="width:540px; height:auto; margin: 0 0 0 120px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Change in Normalised TAV From Baseline</h5><img src="assets/images/saturn.chart-2.jpg" style="width:540px; height:auto; margin: 0 0 0 120px;" alt="chart"/><h5>Patients Achieving LDL-C Goal of <70.0 mg/dL (<1.81 mmol/L)</h5><img src="assets/images/saturn.chart-3.jpg" style="width:540px; height:auto; margin: 0 0 0 115px;" alt="chart"/><div class="result-safty" style="border-top: 2px solid #C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><h6>Clinical and Biochemical AEs and Reasons for Discontinuation of Treatment</h6><img src="assets/images/saturn.chart-4.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/></div></div>',
 '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Percentage of High-Risk Patients Achieving NCEP ATP III LDL-C Goal <100.0 mg/dL (<2.59 mmol/L) at 6 Weeks</h5><img src="assets/images/solar.chart-1.jpg" style="width:555px; height:auto; margin: 0 0 0 125px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Percentage of High-Risk Patients Achieving NCEP ATP III LDL-C Goal <100.0 mg/dL (<2.59 mmol/L) at 12 Weeks</h5><img src="assets/images/solar.chart-2.jpg" style="width:555px; height:auto; margin: 0 0 0 125px;" alt="chart"/><h5>Change From Baseline in Lipid Variables at 12 Weeks of Initial or Titrated Doses in the ITT Population (Observed Cases Dataset)<sup>a</sup></h5><img src="assets/images/solar.chart-3.jpg" style="width:650px; height:auto; margin: 0 0 0 40px;" alt="chart"/><div class="result-safty" style="border-top: 2px solid #C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><h6>Safety Data at 12 Weeks in Safety Population</h6><img src="assets/images/solar.chart-4.jpg" style="width:660px; height:auto; margin: 0 0 0 22px;" alt="chart"/></div></div>',
 '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Reduction in LDL-C at 6 Weeks</h5><img src="assets/images/starship.chart-1.jpg" style="width:555px; height:auto; margin: 0 0 0 125px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>LS Mean Changes From Baseline in Other Lipid Measures at 6 Weeks<sup>a</sup></h5><img src="assets/images/starship.chart-2.jpg" style="width:650px; height:auto; margin: 0 0 0 40px;" alt="chart"/><h5>Proportion of Patients Achieving NCEP ATP III LDL Goal at 6 Weeks</h5><img src="assets/images/starship.chart-3.jpg" style="width:650px; height:auto; margin: 0 0 0 40px;" alt="chart"/><div class="result-safty" style="border-top: 2px solid #C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><ul><li>Study treatments were well tolerated</li><li>Adverse-event profiles were generally similar across treatments; most adverse events were mild to moderate in intensity and considered unrelated to study treatment</li><li>There were no deaths in the study, and no treatment-related serious adverse events were reported</li><li>Discontinuation due to myalgia was similar in all 4 arms of the study (2 patients in each)</li><li>No patients had clinically significant increases in serum creatine kinase (10x ULN)</li><li>One patient receiving atorvastatin 20 mg had a clinically significant increase in alanine aminotransferase (3x ULN on 2 consecutive occasions), but atorvastatin treatment was not stopped</li></ul></div></div>',
 '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Change in LDL-C at 6 Weeks</h5><img src="assets/images/stellar.chart-1.jpg" style="width:500px; height:auto; margin: 0 0 0 171px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Percentage Change From Baseline in HDL-C at 6 Weeks</h5><img src="assets/images/stellar.chart-2.jpg" style="width:535px; height:auto; margin: 0 0 0 145px;" alt="chart"/><h5>High-Risk Patients (%) Achieving 2003 European Goals<sup>a</sup> at 6 Weeks</h5><img src="assets/images/stellar.chart-3.jpg" style="width:560px; height:auto; margin: 0 0 0 120px;" alt="chart"/><div class="result-safty" style="border-top: 2px solid #C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><ul><li>Overall, the trial treatments were well tolerated</li><li>The percentages of patients who reported adverse events during randomised treatment were similar among groups</li><li>The percentages of patients who withdrew from treatment because of adverse events were also similar among groups</li><li>The most common adverse events were pain, pharyngitis, myalgia, and headache</li><li>Changes in clinical laboratory results were generally small</li><li>Five (5) patients (2 patients on atorvastatin 80 mg, 1 patient on atorvastatin 20 mg, 1 patient on simvastatin 40 mg, 1 patient on simvastatin 80 mg) had clinically important ALT elevations (3x ULN at 2 consecutive visits)</li><li>No cases of myopathy (creatine kinase 10x ULN with associated muscle symptoms) were observed</li><li>Two (2) patients (on simvastatin 10 mg) had a clinically important elevation (10x ULN) of creatine kinase, without associated muscle-related symptoms</li></ul></div></div>',
 '<div class="result-primary-endpoint"><h4>RESULTS: PRIMARY ENDPOINT</h4><h5>Percentage Change in LDL-C at 16 Weeks</h5><img src="assets/images/uranus.chart-1.jpg" style="width:495px; height:auto; margin: 0 0 0 125px;" alt="chart"/></div><div class="result-secondary-endpoint" style="border-top: 2px solid #C7C2BA;"><h4>RESULTS: SECONDARY ENDPOINTS</h4><h5>Percentage Change From Baseline in Lipid Profile at 4 Weeks (ITT Population)</h5><img src="assets/images/uranus.chart-2.jpg" style="width:650px; height:auto; margin: 0 0 0 40px;" alt="chart"/><h5>Percentage of Patients Who Achieved 1998 European LDL-C Goal of <115.0 mg/dL (<3.00 mmol/L) at 16 Weeks</h5><img src="assets/images/uranus.chart-3.jpg" style="width:555px; height:auto; margin: 0 0 0 140px;" alt="chart"/><div class="result-safty" style="border-top: 2px solid #C7C2BA;"><h5>RESULTS:</h5><h5>SAFETY</h5><ul><li>Both treatments were well tolerated, with overall incidences of adverse events being similar between the treatment groups (51% with rosuvastatin, 53% with atorvastatin)</li><li>A total of 10 patients experienced serious adverse events (2 in the rosuvastatin group, 8 in the atorvastatin group), none of which were considered by the investigator to be related to study treatment</li><li>Ten (10) patients discontinued because of adverse events, 3 in the rosuvastatin group and 7 in the atorvastatin group</li><li>There were no cases of myopathy</li><li>Myalgia was reported by 3.4% of the patients in the study; none of the cases were associated with a clinically important elevation in CK (>5x ULN)</li><li>There were no clinically important elevations in CK in either group throughout the study and changes in CK were not related to dose of study medication or duration of treatment</li><li>There were no clinically relevant changes in ALAT or ASAT (>3x ULN)</li></ul></div></div>'],
 
      arr_conclusion_reference = ['<div><h4>CONCLUSIONS</h4><p>Rosuvastatin was more effective than atorvastatin in reducing LDL-C and improving other atherogenic lipid and lipoprotein levels over 16 weeks in patients with Type 2 diabetes.</p><p>As a result of greater reductions in LDL-C with rosuvastatin, more patients with Type 2 diabetes mellitus were able to attain the most up-to-date and stringent LDL-C target recommendations available at the time of study conduct.</p></div><div><h4>REFERENCE</h4><p> Betteridge DJ, Gibson JM; for ANDROMEDA Study Investigators. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. <em>Diabet Med</em>. 2007;24:541-549.</p></div><div class="conclusion-pdf"><a href="assets/pdf/andromeda.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<div><h4>CONCLUSIONS</h4><p>Rosuvastatin was more effective than equivalent doses of atorvastatin in reducing LDL-C in African-American individuals with hypercholesterolaemia.</p><div><h4>REFERENCES</h4><p>Ferdinand KC, Clark LT, Watson KE, Neal RC, Brown CD, Kong BW, Barnes BO, Cox WR, Zieve FJ, Isaacsohn J, Ycas J, Sager PT, Gold A; for the ARIES Study Group. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. <em>Am J Cardiol</em>. 2006;97:229-235.</p></div><div class="conclusion-pdf"><a href="assets/pdf/aries.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<div><h4>CONCLUSIONS</h4><p>Treatment with rosuvastatin 40 mg for 2 years in patients with pre-existing coronary disease resulted in significant regression of coronary atheroma burden as assessed by all 3 efficacy endpoints and was well tolerated.</p></div><div><h4>REFERENCE</h4><p>Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R ,Fruchart JC, Tardif J-C, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; for the ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. <em>JAMA</em>. 2006;295:1556-1565.</p></div><div class="conclusion-pdf"><a href="assets/pdf/asteroid.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<div><h4>CONCLUSIONS</h4><p>In patients with end-stage renal disease undergoing haemodialysis, the initiation of treatment with rosuvastatin 10 mg lowered LDL-C but was not associated with a reduction in the composite primary endpoint of myocardial infarction, stroke, or death from cardiovascular causes.</p></div><div><h4>REFERENCE</h4><p>Fellstr&ouml;m BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gr&ouml;nhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, S&uuml;leymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, W&uuml;thrich RP, Gottlow M, Johnsson E, Zannad F; for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing haemodialysis. <em>N Engl J Med</em>. 2009;360:1395-1407. </p></div><div class="conclusion-pdf"><a href="assets/pdf/aurora.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<div><h4>CONCLUSIONS</h4><p>In patients with non-ST-elevation acute coronary syndrome no difference in the primary endpoint (change in the apoB/apoA-1 ratio at 3 months) was observed between rosuvastatin 20 mg and atorvastatin 80 mg. The two treatments induced similar reduction in LDL-C and were well tolerated.</p></div><div><h4>REFERENCE</h4><p>Lablanehe JM, Leone A, Merkely B, Morais J, Alonso J, Santini M, Eha J, Demil N, Licour M, Tardif JC; for the CENTAURUS investigators. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/Apolipoprotein A-I ratio in patients with acute coronary syndrome: results of the CENTAURUS study. <em>Arch Cardiovasc Dis</em>. 2010;103:160-169.</p> </div><div class="conclusion-pdf"><a href="assets/pdf/centaurus.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<p class="content-not-available"> There is no content available at this time.</p>',
  '<div><h4>CONCLUSIONS</h4><p>Rosuvastatin was significantly more effective than equivalent dose atorvastatin in reducing LDL-C levels and improving other aspects of the atherogenic lipid profile, and was well tolerated, in patients with the metabolic syndrome.</p></div><div><h4>REFERENCE</h4><p>Stalenhoef AFH, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, Wilpshaar W. A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study. <em>Eur Heart J</em>. 2005;26:2664-2672.</p> </div><div class="conclusion-pdf"><a href="assets/pdf/comets.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<div><h4>CONCLUSIONS</h4><p>Greater improvements in ApoB/ApoA-I and LDL-C were observed with rosuvastatin compared to double the dose of atorvastatin in subjects with Type 2 diabetes and moderate dyslipidaemia. Both treatments were well tolerated, and showed a comparable safety profile.</p></div><div><h4>REFERENCE</h4><p>Wolffenbuttel BHR, Franken AA, Vincent HH; for the Dutch CORALL Study Group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes &mdash; CORALL study. <em>J Intern Med</em>. 2005;257:531-539.</p></div><div class="conclusion-pdf"><a href="assets/pdf/corall.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<div><h4>CONCLUSIONS</h4><p>Treatment with rosuvastatin 10 mg did not reduce the composite primary endpoint of death from cardiovascular causes or non-fatal myocardial infarction or stroke in vulnerable, elderly patients with ischaemic, systolic heart failure. However, treatment with rosuvastatin 10 mg did reduce the number of hospitalisations for cardiovascular causes.</p></div><div><h4>REFERENCE</h4><p>Kjekshus J, Apetrei E, Barrios V, B&ouml;hm M, Cleland JGF, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, J&aacute;nosi A, Kamensk&yacute; G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJV, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. <em>N Engl J Med</em>. 2007;357:2248-2261.</p></div><div class="conclusion-pdf"><a href="assets/pdf/corona.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<div><h4>CONCLUSIONS</h4><p>Administration of rosuvastatin 2.5-20 mg for 76 weeks resulted in significant regression of coronary plaque in Japanese patients with stable CAD, together with significant LDL-C lowering and an improvement of other lipid parameters.</p></div><div><h4>REFERENCE</h4><p>Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M; for the COSMOS Investigators. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). <em>Circ J</em>. 2009;73:2110-2117.</p></div><div class="conclusion-pdf"><a href="assets/pdf/cosmos.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<div><h4>CONCLUSIONS</h4><p>Rosuvastatin 10 mg was more effective than the comparator statins (atorvastatin 10 mg, simvastatin 20 mg, and pravastatin 40 mg) at lowering LDL-C levels and enabling patients to achieve lipid goals in real-life clinical practice in a large, geographically broad patient population. In addition, all statins studied were well tolerated and it was confirmed that rosuvastatin had a similar safety profile to other statins.</p></div><div><h4>REFERENCE</h4><p>Middleton A, Binbrek AS, Fonseca FAH, Wilpshaar W, Watkins C, Strandberg TE. Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. <em>Curr Med Res Opin</em>. 2006;22:1181-1191.</p></div><div class="conclusion-pdf"><a href="assets/pdf/discovery.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<div><h4>CONCLUSIONS</h4><p>The use of rosuvastatin across its recommended dose range enabled more high-risk patients to achieve recommended LDL-C goals than atorvastatin, while providing a favourable beneficial effect on the lipid profile as a whole. Rosuvastatin and atorvastatin were similarly well tolerated.</p></div><div><h4>REFERENCE</h4><p>Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, Sosef F; on behalf of the ECLIPSE Study Investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE Study. <em>Cardiology</em>. 2008;111:219-228.</p></div><div class="conclusion-pdf"><a href="assets/pdf/eclipse.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<div><h4>CONCLUSIONS</h4><p>The combination of rosuvastatin 40 mg with ezetimibe 10 mg produced greater decreases in LDL-C and allowed more patients to achieve the ATP III LDL-C goal (<100.0 mg/dL; <2.59 mmol/L) than rosuvastatin 40 mg alone. A similar safety profile was observed in both arms.</p></div><div><h4>REFERENCE</h4><p>Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, Duffield E; for the EXPLORER Study Investigators. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). <em>Am J Cardiol</em>. 2007;99:673-680.</p></div><div class="conclusion-pdf"><a href="assets/pdf/explorer.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<p class="content-not-available"> There is no content available at this time.</p>',
  '<div><h4>CONCLUSIONS</h4><p>Rosuvastatin 10 and 20 mg have a similar efficacy in decreasing LDL-C in patients of South Asian origin to that seen in other populations. Rosuvastatin 10 mg was more effective than atorvastatin 10 mg in lowering LDL-C. However, there was not a significantly greater reduction in LDL-C with rosuvastatin 10 mg or 20 mg compared with atorvastatin 20 mg.</p></div><div><h4>REFERENCE</h4><p>Deedwania PC, Gupta M, Stein M, Ycas J, Gold A; for the IRIS Study Group. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). <em>Am J Cardiol</em>. 2007;99:1538-1543.</p></div><div class="conclusion-pdf"><a href="assets/pdf/iris.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<div><h4>CONCLUSIONS</h4><p>Rosuvastatin 20 mg significantly reduced the incidence of major cardiovascular events in apparently healthy individuals without hyperlipidaemia but with elevated high-sensitivity C-reactive protein.</p></div><div><h4>REFERENCE</h4><p>Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. <em>N Engl J Med</em>. 2008;359:2195-2207.</p></div><div class="conclusion-pdf"><a href="assets/pdf/jupiter.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation.<span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<div><h4>CONCLUSIONS</h4><p>Rosuvastatin 20 mg significantly reduced major cardiovascular events in primary prevention patients with elevated hsCRP who had high global cardiovascular risk (10-year Framingham risk score >20% or SCORE risk &ge;5%), but LDL-C levels not requiring pharmacologic treatment.</p></div><div><h4>REFERENCE</h4><p>Koenig W, Ridker PM. Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk &ge;5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities. <em>Eur Heart J</em>. 2011;32:75-83.</p></div><div class="conclusion-pdf"><a href="assets/pdf/jupiter2.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<div><h4>CONCLUSIONS</h4><p>Rosuvastatin 20 mg was as effective as atorvastatin 80 mg in reducing LDL-C, and had a significantly greater effect than atorvastatin 80 mg in raising HDL-C. Rosuvastatin 40 mg was significantly more effective than atorvastatin 80 mg in reducing LDL-C and increasing HDL-C. The safety profile of rosuvastatin 20 mg and 40 mg and atorvastatin 80 mg were similar.</p></div><div><h4>REFERENCE</h4><p>Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR Study). <em>Am J Cardiol</em>. 2012;109:1239-1246.</p></div><div class="conclusion-pdf"><a href="assets/pdf/lunar.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<div><h4>CONCLUSIONS</h4><p>A therapeutic strategy of switching patients from:</p><ul><li>- atorvastatin 10 mg to rosuvastatin 10 mg,</li><li>- atorvastatin 20 mg to rosuvastatin 20 mg,</li><li>- simvastatin 20 mg to rosuvastatin 10 mg, or</li><li>- pravastatin 40 mg to rosuvastatin 10 mg</li></ul><p>can be successful in improving cholesterol goal achievement and the overall lipid profile in patients with CHD or at high risk for CHD, who require relatively aggressive lipid-lowering therapy.</p></div><div><h4>REFERENCE</h4><p>Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, Watkins C, Kallend D, Raza A; for the MERCURY I Study Group. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. <em>Am Heart J</em>. 2004;147:705-713.</p></div><div class="conclusion-pdf"><a href="assets/pdf/mercury_1.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<div><h4>CONCLUSIONS</h4><p>Switching patients from the most commonly used doses of atorvastatin (10 and 20 mg) or simvastatin (20 or 40 mg) to rosuvastatin (10 or 20 mg) is effective strategy for improving LDL-C target achievement.</p></div><div><h4>REFERENCE</h4><p>Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, Weiss R, Cain VA, Raichlen JS. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. <em>Am Heart J</em>. 2006;151:975.e1-975.e9.</p></div><div class="conclusion-pdf"><a href="assets/pdf/mercury_2.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
 '<div> <h4>CONCLUSION</h4><p>Rosuvastatin 40 mg resulted in a reduction in the rate of progression of carotid atherosclerosis in middle-aged individuals with Framingham risk scores lower than 10%.</p></div><div><h4>REFERENCE</h4><p>Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O\'Leary DH, Grobbee DE, Bots ML; for the METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. <em>JAMA</em>. 2007;297:1344-1353.</p> </div><div class="conclusion-pdf"><a href="assets/pdf/meteor.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
   '<div><h4>CONCLUSION</h4><p>Rosuvastatin 10 or 20 mg was effective at enabling patients to achieve and maintain LDL-C and goals over a 12-month period and was well tolerated in the study population. Overall, patients treated with rosuvastatin plus compliance initiatives had no better cholesterol control compared with patients treated with rosuvastatin alone.</p></div><div><h4>REFERENCE</h4><p>Willich SN, Englert H, Sonntag F, V&ouml;ller H, Meyer-Sabellek W, Wegscheider K, Windler E, Katus H, M&uuml;ller-Nordhorn J. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. <em>Eur J Cardiovasc Prev Rehabil</em>. 2009;16:180-187.</p> </div><div class="conclusion-pdf"><a href="assets/pdf/orbital.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<div><h4>CONCLUSION</h4><p>In patients with moderate hypercholesterolaemia, both low-dose rosuvastatin (5 mg) and high-dose rosuvastatin (40 or 80 mg) had no significant effect on the overall carotid plaque burden, but both regimens were associated with a reduction in the lipid rich necrotic core and an increase in the fibrous tissue content of the plaque, over the 2 years of treatment.</p></div><div><h4>REFERENCE</h4><p>Underhill HR, Yuan C, Zhao XQ, Kraiss LW, Parker DL, Saam T, Chu B, Takaya N, Liu F, Polissar NL, Neradilek B, Raichlen JS, Cain VA, Waterton JC, Hamar W, Hatsukami TS. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. <em>Am Heart J</em>. 2008;155:584.e1-584.e8.</p></div><div class="conclusion-pdf"><a href="assets/pdf/orion.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<p class="content-not-available"> There is no content available at this time.</p>',
  '<p class="content-not-available"> There is no content available at this time.</p>',
  '<div><h4>CONCLUSIONS</h4><p>In children with familial hypercholesterolaemia, rosuvastatin 5, 10, and 20 mg lowered LDL-C by 38%, 45%, and 50%, respectively, and 40% of participants reached an LDL-C goal of <110 mg/dL (<2.85 mmol/L). No untoward safety effects were observed.</p></div><div><h4>REFERENCE</h4><p>Avis HJ, Hutten BA, Gagn&eacute; C, Langslet G, McCrindle BW, Wiegman A, Hsia J, Kastelein JJP, Stein EA. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. <em>J Am Coll Cardiol</em>. 2010;55:1121-1126.</p></div><div class="conclusion-pdf"><a href="assets/pdf/pluto.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
'<div><h4>CONCLUSIONS</h4><p>In high-risk patients with hypercholesterolaemia, intensive lipid-lowering therapy with rosuvastatin 40 mg provided greater LDL-C lowering efficacy than atorvastatin 80 mg and enabled more patients to achieve LDL-C treatment targets.</p></div><div><h4>REFERENCE</h4><p>Leiter LA, Rosenson RS, Stein E, Reckless JPD, Schulte K-L, Schleman M, Miller P, Palmer M, Sosef F; on behalf of the POLARIS study investigators. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. <em>Atherosclerosis</em>. 2007;194:e154-e164.</p></div><div class="conclusion-pdf"><a href="assets/pdf/polaris.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
'<div><h4>CONCLUSION</h4><p>In high-risk patients with hypercholesterolaemia, rosuvastatin 10 mg was more efficacious than atorvastatin 20 mg at reducing LDL-C, enabling LDL-C goal achievement, and improving other lipid parameters. Both treatments were well tolerated.</p></div><div><h4>REFERENCES</h4><p>Clearfield MB, Amerena J, Bassand J-P, Hern&aacute;ndez Garc&iacute;a HR, Miller SS, Sosef FFM, Palmer MK, Bryzinski BS. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia &ndash; Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). <em>Trials</em>. 2006;7:35.</p></div><div class="conclusion-pdf"><a href="assets/pdf/pulsar.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
 '<div><h4>CONCLUSIONS</h4><p>Rosuvastatin 10, 20, and 40 mg was significantly more effective than atorvastatin 20, 40, and 80 mg, respectively, in improving the LDL-C/HDL-C ratio in patients with cardiovascular disease and low HDL-C, in addition to significantly improving other components of the lipid profile.</p></div><div><h4>REFERENCE</h4><p>Jukema JW, Liem AH, Dunselman PH, van der Sloot JA, Lok DJ, Zwinderman AH. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. <em>Curr Med Res Opin</em>. 2005;21:1865-1874.</p></div><div class="conclusion-pdf"><a href="assets/pdf/radar.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
 '<div><h4>CONCLUSIONS</h4><p>Maximal doses of rosuvastatin 40 mg and atorvastatin 80 mg resulted in significant regression of coronary atherosclerosis. Despite the lower level of LDL-C and the higher level of HDL-C achieved with rosuvastatin 40 mg, a similar degree of regression of the primary endpoint, percent atheroma volume, was observed in the 2 treatment groups.</p></div><div><h4>REFERENCE</h4><p>Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE. Effect of two intensive statin regimens on progression of coronary disease. <em>N Engl J Med</em>. 2011;365:2078-2087.</p></div><div class="conclusion-pdf"><a href="assets/pdf/saturn.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
 '<div><h4>CONCLUSIONS</h4><p>In a managed care population, rosuvastatin 10 mg resulted in more patients reaching the NCEP ATP III LDL-C goal (<100 mg/dL; <2.59 mmol/L) and produced significantly greater reductions in LDL-C than therapy with atorvastatin 10 mg and simvastatin 20 mg.</p><p>Following dose titration, rosuvastatin 20 mg also reduced LDL-C significantly more than atorvastatin 20 mg and simvastatin 40 mg, and also resulted in more patients reaching the NCEP ATP III LDL-C goal (<100 mg/dL; <2.59 mmol/L).</p></div><div><h4>REFERENCE</h4><p>Insull W Jr, Ghalil JK, Hassman DR, Y&ccaron;as JW, Gandhi SK, Miller E; for the SOLAR Study Group. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. <em>Mayo Clin Proc</em>. 2007;82:543-550.</p></div><div class="conclusion-pdf"><a href="assets/pdf/solar.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
  '<div><h4>CONCLUSIONS</h4><p>Rosuvastatin 10 and 20 mg have a similar efficacy in decreasing LDL-C in Hispanic patients to that observed in Caucasian study populations. Rosuvastatin 10 and 20 mg produced significantly greater reductions in LDL-C than atorvastatin 10 and 20 mg. Rosuvastatin treatment also enabled more patients to reach NCEP ATP III LDL-C goals, particularly high-risk patients.</p></div><div><h4>REFERENCE</h4><p>Lloret R, Ycas J, Stein M, Haffner S; for the STARSHIP Study Group. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). <em>Am J Cardiol</em>. 2006;98:768-773.</p></div><div class="conclusion-pdf"><a href="assets/pdf/starship.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
'<div><h4>CONCLUSIONS</h4><p>Rosuvastatin 10 mg produced a greater reduction in LDL-C compared to atorvastatin 10 and 20 mg, simvastatin 40 mg, and pravastatin 40 mg.</p><p style="margin: 0;">Rosuvastatin 20 mg produced a greater reduction in LDL-C compared to atorvastatin 20 and 40 mg.</p><p style="margin: 0;">Rosuvastatin 40 mg produced a greater reduction in LDL-C compared to atorvastatin 40 and 80 mg.</p><p style="margin: 0;">Drug tolerability was similar across all treatments.</p></div><div><h4>REFERENCE</h4><p>Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). <em>Am J Cardiol</em>. 2003;92:152-160.</p></div><div class="conclusion-pdf"><a href="assets/pdf/stellar.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>',
'<div><h4>CONCLUSIONS</h4><p>Rosuvastatin was significantly more effective than atorvastatin at reducing LDL-C and achieving European LDL-C goals both during the fixed-dose period (10 mg vs. 10 mg) and following dose titration (10&ndash;40 mg vs. 10&ndash;80 mg, respectively) in patients with Type 2 diabetes.</p></div><div><h4>REFERENCE</h4><p>Berne C, Siewert-Delle A; and the URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. <em>Cardiovasc Diabetol</em>. 2005;4:7.</p></div><div class="conclusion-pdf"><a href="assets/pdf/uranus.pdf" target="_blank"><img src="assets/images/pdf.logo.jpg" width="55" height="53" alt="PDF"/></a><p>NOTE: It is the responsibility of every employee within AstraZeneca to act professionally and compliant with the guidelines and to protect AstraZeneca\'s reputation. <span>Use <a href="assets/pdf/UseofThird-PartyInformation.pdf" target="_blank">this link</a> to be compliant when using published information.</span></p></div>'],
      arr_no_of_heighlighted_studies = [3, 1, 3, 1, 2, 2, 1, 3, 1, 3, 2, 11, 11, 11, 1, 1, 11, 2, 11, 11, 2, 11, 2, 2, 2, 2, 11, 11, 11, 3, 11, 1, 2, 3],
      current_index = 0,
      selected_galaxy = '',
      relational_arr = [],
      width_left = [247, 391, 364, 421, 331, 167, 302, 263, 281, 401, 184, 301, 238, 413, 174],
      width_right = [237, 395, 356, 257, 294, 420, 491, 237, 474, 356, 411, 327, 327, 327, 484, 377, 327, 294, 327, 327, 267, 327, 267, 245, 245, 420, 327, 327, 327, 356, 327, 357, 411, 237],
      left_top = [], right_top = [], paging_array = [],
      $disease_content_lists = $('.disease-content-block ul li'),
      $detailed_logo = $('#detail-logo'),
      $main_logo = $('#main-logo'),
      $patient_no = $('.patient-no'),
      $detail_objective = $('.detail-objective'),
      $highlighed_study = $('.highlighted-study'),
      $study_design_content = $('#studydesign-content'),
      $characteristics_content = $('#characteristics-content'),
      $result_content = $('#result-content'),
      $conclusion_content = $('#conclusions-content'),
      $left_horizontal = $('.left-horizontal'),
      $galaxy_content_lists = $('.galaxy-content-block ul li'),
      $right_horizontal = $('.right-horzintal'),
      $adjustable_line = $('#adjustable-line'),
      $outcomes_btn = $('.links-block .buttons input.outcomes'),
      $lipids_btn = $('.links-block .buttons input.lipids'),
      $atherosclerosis_btn = $('.links-block .buttons input.atherosclerosis'),
      paging_limit = 0, copy_paging_limit = paging_limit,
      paging_counter = 0,pointer_to_paging = 0, paging_controller = 0, 
      selected_left_index,copy_selected_galaxy, copy_left_index,
      methods = {
        passRelationalArray: function( relation_array ) {
          relational_arr = relation_array;
        },
        changePagingController: function( attr, msg ) {
          paging_controller = attr;
          if(msg != 'close') {
            methods.setPagingVariables();
          }
        },
        setPagingCounter: function( data ) {
          paging_counter = data;
        },
        changeSelectedLeftIndex: function() {
          var temp_index;
          if(Number(paging_controller) === 1) {
            if(copy_selected_galaxy != selected_galaxy) {
              $disease_content_lists.removeClass('select-galaxy');
              $disease_content_lists.each(function() {
                var $this = $(this);
                if($this.attr('data-for') === selected_galaxy) {
                  temp_index = $this.attr('data-mapping');
                  $this.addClass('select-galaxy');
                  return false;
                }
              });
              selected_left_index = temp_index;
            }
          }
        },
        openPopUp: function( $current_elememt, data_topic ) {
          current_index = $current_elememt.attr('data-content');
          paging_counter = current_index;
          selected_galaxy = data_topic;
          methods.setPagingVariables();
          $detailed_logo.attr('src', arr_logo[current_index]);
          $main_logo.attr('src', detail_arr_logo[current_index]);
          $patient_no.html(arr_no_of_patients[current_index]+' ');
          $detail_objective.html(arr_objectives[current_index]);
          $highlighed_study.html('('+arr_no_of_heighlighted_studies[current_index]+')');
          $study_design_content.html(arr_study_design[current_index]).scrollTop(0);
          $characteristics_content.html(arr_baseline_characteristics[current_index]).scrollTop(0);
          $result_content.html(arr_results[current_index]).scrollTop(0);
          $conclusion_content.html(arr_conclusion_reference[current_index]).scrollTop(0);
        },
        setLeftRightTopPositions: function( obj ) {
          left_top = obj.left_top;
          right_top = obj.right_top;
        },
        setPagingVariables: function() {
          var $left_right_arrow = $('#study-left-arrow, #study-right-arrow, #left-arrow,#right-arrow'), $vertical_line = $('#vertical-line'),temp_index, curr_left_top, curr_right_top, curr_right_bottom, calc_height, heighlighted_calc_height,min_top, heighlighted_right_top, heighlighted_adjustable_line_top;
          if(copy_left_index != selected_left_index) {
            $left_horizontal.removeClass('active-lines').fadeOut();
          }
          if(Number(paging_controller) === 0) {
            $disease_content_lists.each(function() {
              var $this = $(this);
              if($this.attr('data-for') === selected_galaxy) {
                temp_index = $this.attr('data-mapping');
                return false;
              }
            });
            selected_left_index = temp_index;
            paging_array = (relational_arr[temp_index]).split(' ');
            paging_limit = paging_array.length - 1;
            copy_paging_limit = paging_limit;
            pointer_to_paging = paging_array.indexOf(paging_counter.toString());
            if(copy_left_index != selected_left_index) { 
              $('#left-'+selected_left_index).addClass('active-lines');
            }
            $('#right-'+paging_counter).addClass('active-heighlighted');
            for(var b = 0; b < paging_limit; b++) {
              $('#right-'+paging_array[b]).addClass('active-lines');
              if(paging_array[b] != paging_counter) {
                $galaxy_content_lists.eq(paging_array[b]).addClass('select-galaxy');
              }
            }
            curr_left_top = left_top[temp_index];
            curr_right_top = right_top[paging_array[0]];
            curr_right_bottom = right_top[paging_array[paging_limit-1]];
            heighlighted_right_top = right_top[paging_counter];
            if(curr_left_top <= curr_right_top) {
              min_top = curr_left_top;
            } else {
              min_top = curr_right_top;
            }
            if(curr_left_top < heighlighted_right_top) {
              heighlighted_calc_height = heighlighted_right_top - curr_left_top + 6;
              heighlighted_adjustable_line_top = curr_left_top;
            } else {
              heighlighted_calc_height = curr_left_top - heighlighted_right_top + 6;
              heighlighted_adjustable_line_top = heighlighted_right_top;
            }
            calc_height = curr_right_bottom - min_top + 6;
            $vertical_line.addClass('active-lines').css({'left':width_left[temp_index]+'px','top': min_top+'px', 'height': calc_height+'px'});
            $adjustable_line.addClass('active-lines').css({'left':width_left[temp_index]+'px', 'top': heighlighted_adjustable_line_top+'px', 'height': heighlighted_calc_height+'px'});
            $('#left-'+temp_index).addClass('active-lines');
            $('.active-lines').fadeIn();
          } else if(Number(paging_controller) === 1) {
            $right_horizontal.removeClass('active-heighlighted');
            $galaxy_content_lists.removeClass('select-galaxy');
            paging_array = [0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33];
            paging_limit = 34;
            pointer_to_paging = paging_counter;
            $vertical_line.removeClass('active-lines').height(0); // need to change these technique for hiding vertical line
            $right_horizontal.removeClass('active-lines');
            $('#right-'+paging_counter).addClass('active-heighlighted');
            $disease_content_lists.each(function() {
              var $this = $(this);
              if($this.attr('data-for') === selected_galaxy) {
                temp_index = $this.attr('data-mapping');
                return false;
              }
            });
            selected_left_index = temp_index;
            if(copy_left_index != selected_left_index) {
              $('#left-'+selected_left_index).addClass('active-lines').fadeIn();
            }
        }
        copy_left_index = selected_left_index;
        if(paging_limit == 1)
         {
           $left_right_arrow.css('visibility', 'hidden');
         } else {
           $left_right_arrow.css('visibility', 'visible');
         }
        },
        setHeighlightedBlocks: function(pointer, pointer_to_paging, action) {
          var next_elem = Number(pointer), $darker_elem, prev_pointer;
          $galaxy_content_lists.removeClass('select-galaxy-darker');
          if(Number(paging_controller) === 1) {
            if(copy_selected_galaxy != selected_galaxy) {
              $galaxy_content_lists.removeClass('select-galaxy');
            }
          } else if(Number(paging_controller) === 0) {
            if(action === 'decreament') {
              if(pointer_to_paging > 0) {
                prev_pointer = pointer_to_paging - 1;
              } else {
                prev_pointer = paging_limit - 1;
              }
            } else if(action === 'increament') {
              if(pointer_to_paging < (paging_limit - 1)) {
                prev_pointer = pointer_to_paging + 1;
              } else {
                prev_pointer = 0;
              }
            }
            $galaxy_content_lists.eq(paging_array[prev_pointer]).addClass('select-galaxy');
          }
          $darker_elem = $galaxy_content_lists.eq(next_elem);
          $darker_elem.addClass('select-galaxy-darker');
        },
        changeSelectedButtons: function(pointer) {
          $outcomes_btn.removeClass('selected-outcomes');
          $lipids_btn.removeClass('selected-lipids');
          $atherosclerosis_btn.removeClass('selected-atherosclerosis');
          $('.links-block .buttons input').css('color', '#830051');
          var $next_element = $galaxy_content_lists.eq(pointer);
          if($next_element.hasClass('lipids')) {
            $lipids_btn.addClass('selected-lipids').css('color', '#fff');
          }
          if($next_element.hasClass('atherosclerosis')) {
            $atherosclerosis_btn.addClass('selected-atherosclerosis').css('color', '#fff');
          }
          if($next_element.hasClass('outcomes')) {
            $outcomes_btn.addClass('selected-outcomes').css('color', '#fff');
          }
        },
        changeHeighlightedLines: function( pointer, pointer_to_paging, action ) {
          var paging_length = (paging_array.length) - 1, previous_pointer;
          if(action === 'decreament') {
            if(pointer_to_paging > 0) {
              previous_pointer = pointer_to_paging - 1;
            } else {
              previous_pointer = paging_limit - 1;
            }
          } else if(action === 'increament') {
            if(pointer_to_paging < (paging_limit - 1)) {
              previous_pointer = pointer_to_paging + 1;
            } else {
              previous_pointer = 0;
            }
          }
          if(previous_pointer < 0) {
            previous_pointer = paging_length - 1;
          } else if(previous_pointer >= paging_length) {
            previous_pointer = 0;
          }
          var curr_left_top = left_top[selected_left_index], curr_right_top = right_top[pointer],curr_left_width = width_left[selected_left_index], 
              max, min, calc_height;
          if(curr_left_top >= curr_right_top) {
            max = curr_left_top;
            min = curr_right_top;
          } else {
            max = curr_right_top;
            min = curr_left_top;
          }
          calc_height = max - min + 6;
          if(Number(paging_controller) === 0) {
            $adjustable_line.addClass('active-lines').animate({top: min+'px', height: calc_height+'px'},10);
            $('#right-'+paging_array[previous_pointer]).removeClass('active-heighlighted').addClass('active-lines');
            $('#right-'+pointer).removeClass('active-lines').addClass('active-heighlighted');
          } else if(Number(paging_controller) === 1) {
            $left_horizontal.removeClass('active-lines').css('display', 'none');
            $right_horizontal.removeClass('active-lines , active-heighlighted').css('display', 'none');
            $adjustable_line.addClass('active-lines').animate({left: curr_left_width+'px', top: min+'px', height: calc_height+'px'},10);
            $('#right-'+pointer).removeClass('active-lines').addClass('active-heighlighted');
            $('#left-'+selected_left_index).addClass('active-lines');
            $('.active-lines, .active-heighlighted').css('display', 'block');
          }
        },
        pagingStart: function( pointer_to_paging, action ) {
          var pointer = paging_array[pointer_to_paging];
          methods.setPagingCounter(pointer);
          copy_selected_galaxy = selected_galaxy;
          selected_galaxy = $galaxy_content_lists.eq(pointer).attr('data-topic');
          methods.changeSelectedButtons(pointer);
          methods.changeSelectedLeftIndex();
          methods.setHeighlightedBlocks(pointer, pointer_to_paging, action);
          methods.changeHeighlightedLines(pointer, pointer_to_paging, action);
          $detailed_logo.attr('src', arr_logo[pointer]);
          $main_logo.attr('src', detail_arr_logo[pointer]);
          $patient_no.html(arr_no_of_patients[pointer]+' ');
          $detail_objective.html(arr_objectives[pointer]);
          $highlighed_study.html('('+arr_no_of_heighlighted_studies[pointer]+')');
          $study_design_content.html(arr_study_design[pointer]).scrollTop(0);
          $characteristics_content.html(arr_baseline_characteristics[pointer]).scrollTop(0);;
          $result_content.html(arr_results[pointer]).scrollTop(0);;
          $conclusion_content.html(arr_conclusion_reference[pointer]).scrollTop(0);;
          
        },
        handelingNext: function() {
          if(pointer_to_paging < paging_limit - 1) {
            pointer_to_paging++;
          } else if(pointer_to_paging == paging_limit - 1) {
            pointer_to_paging = 0;
          }
          methods.pagingStart(pointer_to_paging, 'decreament');
        },
        handelingPrevious: function() {
          if(pointer_to_paging > 0) {
            pointer_to_paging--;
          } else if(pointer_to_paging == 0) {
            pointer_to_paging = paging_limit - 1;
          }
          methods.pagingStart(pointer_to_paging, 'increament');
        }
      };
  $.fn.clickHandeling = function( method ) {
    if(methods[method]) {
      return methods[method].apply(this, Array.prototype.slice.call(arguments, 1));
    } else if(typeof method === 'object' || !method) {
      return methods.init.apply(this, arguments);
    } else {
      alert('Method '+ method +' is not valid method for setRelationship');
    }
  }
})(jQuery);

